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ABSTRACT 
Title: Study on Lower Urinary tract Infections and stent colonization in patients with 
Double- J ureteral stents in a tertiary care hospital. 
Introduction: Double-J ureteral stents represent a minimally invasive alternative to 
preserve urinary drainage whenever ureteral patency is deteriorated or is under a 
significant risk to be occluded due to extrinsic or intrinsic etiologies. Like all synthetic 
medical intracavitary devices, Double-J ureteral stent also offers a suitable surface for 
microbial colonization by biofilm forming microorganisms. Recognizing the colonization 
is very important for prevention of bacteremia during manipulation.  
Aim of the study: To assess the extent of stent colonization and to determine the 
incidence of urinary tract infections in patients with indwelling Double-J ureteral stents. 
Materials and Method: Between November 2014 and August 2015, 100 patients (20-75 
years old) who underwent Double J ureteral stent placement for ureteral obstruction were 
enrolled in this cross sectional study. Urine sample for culture were collected from these 
patients prior to stent insertion and on the day of stent removal. Stents were removed 
under sterile conditions with the help of a cystoscope. Double J ureteral stent cultures 
were also performed on 5% sheep blood agar plate. 
Results: Out of the one hundred patients who were treated with Double-J ureteral stents 
for ureteral obstruction, 67% of patients had Double-J ureteral stent colonization and only 
36% had urinary tract infection. The duration of retention of Double-J ureteral stent in the 
urinary tract had a statistically significant influence on the rate of colonization of the 
Double-J ureteral stent and bacteriuria (p< 0.001). Escherichia coli was the predominant 
pathogen (32.4%) isolated from Double-J stent culture as well as from the culture of 
urine samples (34.2%) from patients treated with Double-J ureteral stent. 
Conclusion: As microbial ureteral stent colonization does not necessarily lead to 
bacteriuria, negative urine culture does not rule out biofilm formation, hence urine culture 
has a low predictive value for ureteral stent colonization. 
Key Words: Biofilm, Double-J ureteral stent, Microbial colonization, Urinary tract 
infection. 
 
 
 
 
 1 
INTRODUCTION 
Worldwide production of biomedical devices and engineered 
medical tissue is rapidly increasing. The insertion of indwelling or 
implanted foreign polymer bodies, such as prosthetic heart valves, 
cardiac pacemakers, total artificial hearts and total joint replacements or 
other orthopaedic devices, as well as intravascular catheters, renal 
dialysis shunts, cerebrospinal fluid (CSF) shunts or continuous 
ambulatory peritoneal dialysis catheters, has become an indispensable 
part of modern medical care.  
Among all currently used medical devices urinary catheters and 
stents are the most common.
 [1]
 The ability to manipulate the urinary 
tract without the need for an open surgical incision differentiates 
urology from other disciplines. Such intervention may be required for 
diagnostic or therapeutic purposes or both.  
The Double-J ureteral stent is a catheter or tube placed within the 
ureteral lumen in order to maintain its patency due to obstruction by 
intrinsic or extrinsic etiologies such as ureteral stones, strictures, 
congenital anomalies, retroperitoneal tumors or fibrosis.  The tips of 
these stents are J-shaped and urologists place them endoscopically over 
the guidewire. The double coil design at proximal and distal ends 
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securely anchor the stent in the upper urinary tract (renal pelvis and 
upper calyx) and the bladder and provide a self -retaining capability .  
In the present scenario usage of Double-J ureteral stent has 
become one of the basic and most valuable tools in day to day urological 
practice, therefore the complications related to the usage of stents are 
also more frequent than before. Any implanted medical device may 
become infected with a bacterial biofilm.
[2]
 Scientists have recently 
realized that in nature, more than 99% of all bacteria exists as 
biofilms.
[3] 
Microbial colonization of the indwelling device can be a 
prelude to both infection and malfunction of the device.  
Device-associated infections in urology are complicated by 
majority of uropathogens including both Gram positive and Gram 
negative bacteria, as well as yeast which are able to form complex 
biofilm communities.
[4-6] 
Organisms growing in the biofilm are 
relatively protected from both antimicrobials and host defenses. 
[7]
 
The microorganisms in biofilms are difficult or impossible to treat 
with antimicrobial agents and their detachment from the device may 
result in infection. Therefore, it is recommended to prevent their 
formation rather than treatment. The present study is designed with the 
aim to isolate and identify the microorganisms which colonize the 
Double-J ureteral stents and which cause urinary tract infections.  
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AIMS AND OBJECTIVES 
AIM OF THE STUDY 
           To assess the extent of stent colonization and to determine the 
incidence of urinary tract infections in patients with indwelling Double-
J ureteral stents. 
OBJECTIVES 
1) To isolate, identify and determine the antimicrobial susceptibility 
pattern of the microorganisms causing stent colonization in 
patients treated with indwelling Double- J ureteral stents. 
2) To determine the incidence of urinary tract infections in patients 
with Double-J ureteral stents. 
3) To compare the relationship between colonization of the Double-J 
ureteral stent and the microorganisms isolated from urine samples 
from these patients. 
4) To correlate the relationship between duration of Double-J 
ureteral stent placement and its colonization.  
5) To phenotypically detect biofilm production of the isolates from 
the colonized Double-J ureteral stents. 
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REVIEW OF LITERATURE 
Hippocrates in 4
th
 century surmised that the kidney had the 
faculty of extracting and separating moisture from the blood; this 
moisture descends into bladder.
 [8]
The urinary system is the structure 
which precisely maintains the chemical environment of the body, 
performs various excretory, regulatory and secretory functions. The 
urinary tract allows for the excretion of urine produced by the kidneys.                                                                                                                                      
ENDOSCOPIC ANATOMY OF URINARY TRACT 
         The knowledge of the normal endoscopic anatomy is a prerequisite 
for accurate endoscopic screening of the urinary tract.  The surface of the 
distended bladder can be divided into several regions: the vesical neck, 
which limits the bladder inferiorly, is the major landmark and reference 
point in the anatomy of the bladder; the trigone corresponds to the area 
limited by the ureteral orifices and the intravesical urethral opening; the 
elevation extending between the ureteral orifices is known as the 
interureteric ridge or mercier‟s bar. The base (fundus) of the bladder is 
located posterior to the trigone. The bladder mucosa appears relatively 
smooth with intravesical protrusions.
 [9, 10]
 
The normal non-refluxing ureteral orifice may be prominent on 
endoscopy; or as an inconspicuous slit that can be identified only on 
close examination. Starting from the ureteral orifice, the intravesical 
 5 
section of ureter extends for about 1.5 cm. The intramural part runs 
obliquely through the bladder musculature at the detrusor hiatus for 
about 1cm, represents the narrowest part of the ureter -ureterovesical 
junction (UVJ) which requires dilatation before introduction of large 
caliber instruments. The other two narrow areas at the pelvic brim and at 
the ureteropelvic junction (UPJ) appear as slightly stenotic and 
relatively non-distensible. 
[9, 10]
 
         The normal renal pelvis is funnel shaped with the apex of the 
funnel leading into the UPJ. As the ureteroscope enters the renal pelvis, 
the ostia of the major calyces leading to the upper, middle and lower 
poles of the kidney appear as circular openings connected to the apex  by 
a long tubular portion, the infundibulum. Carinae separate the major 
calyces from the renal pelvis. The final structures visible are the minor 
calyces with their calyceal fornix surrounding the renal papilla. 
[9, 10] 
URINARY TRACT INFECTIONS 
Urinary tract infection (UTI) is a spectrum of disease caused by 
microbial invasion of genitourinary tract that extends from the renal 
cortex of the kidney to urethral meatus. UTI are common, affect men 
and women of all ages, and vary dramatically in their presentation and 
sequelae. Urinary tract infection may involve only the lower urinary 
tract or both the upper and lower tracts. Lower UTI‟s are cystitis, 
urethritis, prostatitis. Upper UTI‟s are pyelonephritis, intra -renal 
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abscess and perinephric abscess which is usually a late complication of 
pyelonephritis. 
Uncomplicated UTI – symptomatic urinary tract infection 
characterized by frequency, urgency, dysuria, or supra pubic pain in a 
structurally and neurologically normal urinary tract.
 [11]
  
Complicated UTI – symptomatic urinary tract infection 
associated with factors that increase the chance of acquiring bacteria and 
decrease the efficacy of therapy. The urinary tract is functionally or 
structurally abnormal, (e.g., indwelling catheters and renal calculi) the 
host is compromised and or the bacteria have increased virulence or 
antimicrobial resistance. 
[11]
 
INCIDENCE AND EPIDEMIOLOGY 
UTI‟s are considered to be the most common bacterial infection 
worldwide. In developed countries like USA, it has been estimated that 
symptomatic UTIs result in as many as 7 million visits to outpatient 
clinics, 1 million visits to emergency departments, and 100,000 
hospitalizations annually.
 [12]
   
Urinary tract infections are one of the most common nosocomial 
infections accounting for approximately 40 % of all hospital acquired 
infection and 80% of this are associated with use of urinary catheters 
and indwelling stents.
[13] 
Experts at the Centers for Disease Control and 
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Prevention have estimated that biofilms are associated with 65% of 
nosocomial infections.
[14] 
ETIOLOGIC AGENTS 
 Organisms causing UTI are derived primarily from the aerobic 
members of the fecal flora. Majority of uncomplicated urinary 
tract infections are caused by a single organism. In contrast, 
infections among hospitalized patients, patients with urinary 
catheters, or individuals  with structural abnormalities of the 
urinary tract may be polymicrobial 
[15]
 
 The most common pathogens are Gram negative bacilli. 
Escherichia coli cause about 80% of acute infections in patients 
without urinary tract abnormalities. Other Gram negative bacilli 
included are Proteus mirabilis and Klebsiella pneumoniae, which 
colonize the enteric tract. Enterobacter spp., Serratia spp., and 
Pseudomonas aeruginosa are infrequent in the outpatient 
population, but they are more frequent in patients with 
complicated UTI.
 [15]
                   
 Staphylococcus saprophyticus, a Gram positive coagulase 
negative staphylococcus, causes about 10% of infections among 
young, sexually active women.
 [15]
 
 Other less frequently isolated agents are other Gram negative 
bacilli, such as Acinetobacter and Alcaligenes spp., other 
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Pseudomonas spp., Citrobacter spp., Gardnerella vaginalis and 
Group B streptococcal spp. Bacteria such as Mycobacteria, 
Chlamydia trachomatis, Ureaplasma urealyticum, Campylobacter 
spp., Haemophilus influenza and certain Corynebacterium spp. 
(e.g., C. renale) are rarely recovered urine
 [15]
 
 Candida albicans is the most common cause of funguria, followed 
by Candida glabrata, Candida tropicalis, Candida parapsilosis, 
Candida krusei, and other yeasts .
[16]
 
 The most frequently isolated strains from catheterized patients are 
Enterococcus faecalis, Pseudomonas aeruginosa, and Escherichia 
coli, while the strongest biofilm producers are Proteus mirablis, 
Enterococcus faecalis, Candida tropicalis and Staphylococcus 
aureus.
[17]
 
ROUTES OF INFECTION  
The two important routes by which bacteria can invade and spread 
within the urinary tract are the ascending and hematogenous pathways.  
HEMATOGENOUS ROUTE 
Infection of the renal parenchyma by blood-borne organisms 
occurs in humans, but less commonly than by the ascending route. The 
kidney is frequently the site of abscesses in patients with bacteremia or 
endocarditis caused by a Gram positive organism, Staphylococcus 
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aureus; infections of the kidney with Gram negative bacilli rarely occur 
by the hematogenous route.
 [18]
 
ASCENDING ROUTE 
Most uropathogens originate in the rectal flora and enter the 
bladder via the urethra. The female urethra is short and proximal to the 
vulvar and perineal areas, making contamination likely .
 [18]
 Urinary tract 
infections in women develop when uropathogens from the fecal flora 
colonize the vaginal introitus, which is one of the critical initial steps in 
the pathogenesis of both acute and recurrent UTI.
  
                       
Instrumentation of the urinary tract such as urinary 
catheterization, cystoscopy facilitate ascent of microorganisms and is 
the most common cause of hospital-acquired UTIs in both sexes. Once 
the bacteria ascend into the bladder, they may multiply and then pass up 
the ureters to the renal parenchyma particularly if vesicoureteral reflux 
is present. 
[15] 
Incomplete emptying of the bladder due to mechanical reasons 
like bladder neck obstruction, urethral valves, urethral strictures, 
prostatic hypertrophy or neurogenic malfunction can lead to frequent 
urinary tract infections due to bladder over distension, which may 
interfere with local defense mechanisms and also require frequent 
instrumentation of the urinary tract.
 [18] 
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PATHOGENESIS
 
Symptomatic bacteriuria is highly correlated with the presence of 
bacteria that mediate attachment to uroepithelial cells. Bacteria with 
enhanced adherence to vaginal and periurethral cells colonize the 
anatomic regions adjacent to the urethral orifice. Binding to the 
uroepithelial surface, in turn, prevents bacterial washout during 
micturition and is the first step to bacterial invasion.
 [18] 
The adhesive properties of uropathogenic Escherichia coli 
(UPEC) are facilitated by Type 1 and P fimbriae, filamentous surface 
organelle. The attachment of Type 1 fimbriae is blocked by mannose 
sensitive (MS) adhesins, while the latter is by mannose resistant (MR) 
adhesins. The P fimbriae augment the virulence of UPEC by allowing 
more efficient spread from the intestinal tract to the urinary tract and 
thereby causing ascending infection.
 [18] 
After entry into the bladder, MS-adhesins which are present on 
the majority of the Enterobacteriaceae, facilitate attachment to the 
bladder epithelium. However, when the bacteria ascend to the renal 
parenchyma, they undergo phase variation and do not express Type 1 
fimbriae which enhance phagocytosis. Rather, in the upper urinary tract, 
P fimbriae are expressed, allowing attachment to renal parenchymal 
cells resulting in pyelonephritis and inducing bacteremia.
 [18] 
Proteus 
spp. is able to hydrolyze urea via urease production which results in an 
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increase in the pH of urine that is directly toxic to kidney cells and also 
stimulates the formation of kidney stones.
 [15, 19] 
Motile organisms 
ascend the urinary tract against the flow of urine and cause 
pyelonephritis.  Some organisms demonstrate greater production of K 
antigen (capsule or outer cell wall antigen); this antigen protects 
bacteria from being phagocytosed.
 [18] 
In contrast among Gram positive organisms, Staphylococcus 
saprophyticus, which adheres significantly better to uroepithelium than 
do Staphylococcus aureus or Staphylococcus epidermidis, is a frequent 
cause of lower urinary tract infections, whereas Staphylococcus aureus 
uncommonly causes cystitis and ascending pyelonephritis.
 [18]  
 
In an individual with structural abnormalities of the ur inary tract 
or with a catheter, even organisms of low pathogenicity can cause 
infection of bladder, kidney, or both, and the above-described properties 
of the bacteria for pathogenesis are not essential.
 [18] 
URETERAL STENTS
 
Ureteral stents represent the most mature application of an 
indwelling endoluminal splint. Stents are hollow tubes that work by 
draining fluid both around and through their structure and although used 
commonly in urology, have found applications in cardiac and 
hepatobiliary surgery. 
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HISTORY OF STENTS
  
 Gustav Simon performed the first reported case during the 19 th 
century by placing a tube in the ureter during open cystostomy.
[20] 
 The era of the modern long-term indwelling ureteral stent began 
in 1967 when Zimskind reported the use of open-ended silicone 
tubing inserted endoscopically to bypass malignant ureteral 
obstruction or ureterovaginal fistulas.
 [20] 
 Finney in 1978, refined the design of ureteral stent by describing 
a Double-J stent with oppositely directed loops at the renal and 
vesical ends to prevent migration. Today the Double-J ureteral 
stent is considered to be the „Gold standard‟ of stents.  [20] 
    PROPERTIES OF AN IDEAL STENT 
An “ideal” stent should demonstrate optimal flow characteristics , 
prevent migration and must be well tolerated by the patient. It should 
also be biocompatible, biodurable, radioopaque, easy to insert and 
remove and provide cost benefit to the patient and hospital. With such 
high expectations, tremendous improvements have taken place in the 
field of stent biomaterials, design and texture; however, no currently 
available device fulfills all of the criteria for the “ideal” stent.  [21, 22]  
DOUBLE-J URETERAL STENT  
Double-J ureteral stents are made of polyurethane, polyethylene, 
or silicone. Double-J ureteral stent has both a proximal and distal curl, 
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designed to retain its position within the ureter and end-holes and 
multiple side-holes that allow urine to drain freely from the kidney's 
upper collecting system, down through and around the stent, and into the 
bladder.
 [23]   
CURRENT STENT BIOMATERIALS 
 Initially Polyethylene, a synthetic polymer was used in stent 
construction, as it was flexible, odorless, translucent, and non-
reactive in the body, but was abandoned due to its stiffness, 
brittleness, and tendency to fragment.
 [20]
 
 Currently Silicone one of the most lubricious materials available 
is the most biocompatible stent material as it is most resistant to 
biofilm formation, infection and encrustation. However it‟s 
softness and elasticity make it difficult to pass through tortuous 
and tight ureters.
 [20]
 
 Polyurethane which is the most common class of polymer 
currently used in stents, is highly versatile and inexpensive, but 
has been shown to induce significant epithelial ulceration and 
erosion than other materials with limited durability and slow in- 
vivo biodegradation.
 [20]
 
      INDICATIONS FOR URETERIC STENT INSERTION 
The indications for stenting can be broadly divided into three     
categories 
[24, 25] 
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A) For relief of obstructive uropathy 
Intrinsic 
 Renal or Ureteric calculi 
 Stricture 
 Ureteropelvic Junction obstruction 
Extrinsic  
 Hydronephrosis of pregnancy 
 Extramural compression of ureter by Retroperitoneal tumors or 
fibrosis 
B) Adjunct to ureteral surgery 
Preoperative placement done prior to 
 Complicated surgery to identify ureter 
 Extracorporeal shock wave Lithotripsy (ESWL) in case of solitary 
kidney and stone >15mm in diameter.  
Intra operative insertion is done following: 
 Ureteroscopy 
 Steinstrasse ( street of stone )post ESWL 
 Reconstructive procedures - Ureteroneocystotomy, 
Ureteroureterostomy, Cystectomy, Endopyelotomy/ pyeloplasty  
and urinary diversion 
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C) Management of urine leak 
 From trauma or surgery 
 Due to ureteral fistula 
Urolithiasis 
Urolithiasis is a common disease that is associated with 
significant morbidity and a prevalence of 3-20% worldwide. 
[26, 27] 
Stones can either form in the bladder or the kidneys. Renal stones can 
subsequently move into the ureters where, depending on the size, they 
will either continue to pass into the urinary bladder or cause obstruction 
of the ureter causing excruciating pain and potential renal dysfunction. 
Extracorporeal shock wave lithotripsy (ESWL) and Ureterorenoscopy 
(URS) are currently the most common treatment options in clinical 
practice.
 [28]
  
     Post ureteroscopy stenting 
 In ureteroscopy the stone is disrupted using holmium laser under direct 
vision with a rigid or flexible ureteroscope.
 [29]
 The principle behind the 
routine procedure of leaving a stent post ureteroscopy is to avoid 
ureteral obstruction secondary to ureteral edema and stone fragments. 
Several studies have suggested that stenting is not routinely required 
following uncomplicated ureteroscopy without ureteric dilation .
 [30-32] 
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Stenting as an adjunct to extracorporeal shock wave lithotripsy 
(ESWL)  
ESWL, utilizes underwater energy wave focused on the stone to 
shatter it into small passable fragments. ESWL is suitable for stones that 
are smaller than 2cm and lodged in the upper or middle calyx.
 [33]
 
Stenting prior to ESWL is thought to preclude renal obstruction from 
stone fragments following ESWL. Some researchers believe that routine 
use of ureteral stents in ESWL patients not only lack efficacy to prevent 
renal obstruction, but may, in fact impede the passage of stone 
fragments following ESWL.
 [34] 
STENT SIZE SELECTION 
Double -J ureteral stents are available in sizes from 4.8-5-5.5-6 Fr / 16-
24-26-28 cm, where Fr stands for French scale, one Fr is equal to 
0.33mm. The most commonly used adult size is 26cm/ 4.8Fr. These 
generally admit 0.028"-0.035" guide wires. A paediatric patient 
necessitates the estimation of the ureteric length and then selecting a 
smaller stent length such as 24/4.8 or 20/4.8.
 [24]
 
STENTING TECHNIQUE 
Stent placement is usually made using either a cystoscope or by 
percutaneous technique under fluoroscopic guidance. Placement is done 
by antegrade or retrograde technique. A nephrostomy tube is usually 
placed first, percutaneously, through the flank and into the kidney prior 
STENTING TECHNIQUE 
 
 
POSITION OF DOUBLE-J URETERAL STENT AFTER 
PLACEMENT 
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to an antegrade or retrograde procedure. In this way, the kidney function 
can be assessed to ensure the kidney's ability to maintain an internal 
stent before insertion.
 [23, 35]  
ANTEGRADE TECHNIQUE         
Double-J stent is placed in an antegrade direction through the 
nephrostomy tube's track, down through the ureter into the bladder over 
a guide wire.
 [23] 
 
RETROGRADE TECHNIQUE 
A retrograde placement requires passing a guide wire from the 
nephrostomy site through the ureter to the bladder, where it is snared 
and pulled out through the urethra. The stent is passed over the wire in a 
retrograde direction until it reaches the correct position within the upper 
collecting system. Once the stent is in place, the guide wire is removed, 
allowing the ends of the stent to curl into the J shape and anchor the 
stent within the kidney and bladder. In a variation of this technique, the 
physician doesn't place the nephrostomy catheter, instead does the 
retrograde placement cystoscopically, with a wire from below.
 [23, 35] 
Most stents can be safely removed under local anaesthesia using a 
cystoscope with a bi-prong /triprong forceps. 
DURATION OF STENT PLACEMENT 
 An ideal safe minimal optimal duration for stenting has not been 
described.  Stenting following ureteroscopy or ESWL for ureteric calculi is 
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generally removed in 2-3 weeks. A difficult percutaneous nephrolithotomy 
(PCNL) or ESWL is associated with a risk of significant "steinstrasse" and may 
necessitate stenting for up to 2-3 months. Patients with chronic renal failure 
due to obstructive uropathy or malignant ureteric obstruction may need lifelong 
stenting with a 3-monthly serial change. 
[24] 
STENT MONITORING 
Stent monitoring includes regular weekly urine culture, serum 
creatinine and an X-ray KUB showing kidney, ureter and urinary 
bladder. Internal ureteral stent patency can be evaluated by colour-coded 
Doppler sonography (CCDS) or by a micturating 
cystourethrography.
[36]
 CCDS may have sensitivity up to 100% besides 
being completely non-invasive; a simultaneous KUB ultrasound scan 
can be done to detect any hydroureteronephrosis.  
COMPLICATIONS OF DOUBLE-J STENT INSERTION 
1) Stent syndrome 
The most common complication is „Stent syndrome‟. It consists of 
a constellation of clinical symptoms such as frequency, urgency, flank 
pain, suprapubic discomfort and sometimes with haematuria  and 
incontinence. Stent acts as a foreign body that irritates the ureteral and 
bladder wall.
 [37] 
Other complications are 
(38-43) 
2) Malposition of stent  
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3) Migration of Stent 
4) Inadequate relief of obstruction 
5) Stent fracture 
6) Encrustation 
7) Ureteral erosion & Fistulization 
8) Forgotten Stent 
Urinary tract infections following stent insertion 
     Urinary tract infection may develop early as a complication of 
instrumentation of a previously sterile urinary tract, or later as an 
extension of the underlying disease process. The presence of a foreign 
body may also lead to colonization of the urinary tract, and ultimately of 
the stent itself.   
BIOFILM 
     Biofilms and their related complications are a significant cause 
of morbidity in the patients requiring a urinary device and remain the 
most common cause of stent failure.
[44]
 Although chronically stented 
patients are mostly at risk for developing biofilm and the subsequent 
sequelae, even patients with short-term (7-14days) indwelling stents are 
at risk, especially those with immunodeficiencies, other concurrent 
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medical conditions or in those with urinary tract anatomic abnormalities 
or reconstructions of the urinary tract.  
Biofilm structure 
     Biofilms are defined as “an assemblage of microbial cel ls that 
are irreversibly associated with a surface and enclosed in a matrix of 
primarily polysaccharide material allowing growth and survival in 
sessile environment”. [45] 
  Confocal scanning laser microscope (CSLM) revealed that 
biofilm is composed primarily of 15% by volume of 
microcolonies of different species of microbial cells and 85% of 
matrix material.
 [44] 
 Extracellular polymeric substance (EPS) is primarily made up of 
polysaccharides, which may be neutral or polyanionic. The 
anionic property is due to the presence of uronic acids (D-
glucuronic, D-galactouronic and mannuronic acids) and ketal linked 
pyruvate which helps in the association of divalent cations such as 
calcium and magnesium, which in turn cross-link with the polymer 
strands and provide greater binding force in a developed biofilm.
[46]
  
 Backbone of the EPS contains 1, 3- and 1, 4-β linked hexose 
residues. The amount of EPS produced varies with different 
organisms and increases with the age of the biofilm.
[47]
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Stages in biofilm formation and growth 
There are five major stages in biofilm colony formation 
[48, 49]
 
 Transport and initial attachment of microbes,  
 Irreversible adhesion or attachment,  
 Microcolony formation,  
 Maturation of the biofilm, and  
 Detachment and dispersion of the cells.  
The size of the biofilm can range from a few isolated monolayers 
to 400 cells deep, effectively covering the complete luminal area of the 
device and reaching a population of up to 5×10
9
CFU.
 [11]
 The 
distribution of biofilm is influenced by the growth rate of 
microorganisms on a surface and the strategies used by them to spread 
over the surface are also important for colonization.
 [50] 
The biofilm is usually built up of three layers,
 [17] 
 The linking film which attaches to the surface of tissue or 
biomaterials. 
 The base film of compact microorganisms. 
 The surface film as an outer layer, where planktonic organisms 
can be released free floating and spreading over the surface  
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Susceptibility to antimicrobials 
and Host immune responses 
 
STEPS INVOLVED IN BIOFILM FORMATION AND ITS 
CONSEQUENCES 
Ureteral stent placement 
 
Deposition of Tamm-Horsfall glycoprotein, various ions, proteins, 
polysaccharides and organic molecules to form a conditioning film.  
 
Bacterial adhesion within minutes of insertion 
 
Irreversible attachment due to bacterial polysaccharides  
 
Multiplication of bacteria while emitting chemical signals 
 
Formation of microcolonies 
 
 
Dispersion of biofilm cells by cell growth and division or shearing of 
biofilm aggregates 
        
Urinary tract infection     Antibody production 
and Encrustation     against detached cells 
        
Tissue damage by immune  
complex deposition 
MECHANISM OF ANTIMICROBIAL RESISTANCE IN BIOFILM 
Biofilms evade anti microbial challenges by multiple mechanisms 
which are enumerated below, 
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 The negatively charged EPS secreted by biofilm bacter ia, acts as a 
physical/chemical barrier preventing penetration of antibodies or 
antibiotics and also functions as an ion-exchange resin capable of 
binding a large number of the antibiotic molecules that are 
attempting to reach the embedded biofilm cells (extrinsic 
resistance) .
[51,52]
 
 Bacteria within a biofilm activate many genes which alter the cell 
envelope, the molecular targets and the susceptibility to 
antimicrobial agents (intrinsic resistance). 
[17] 
Phenotypic changes 
caused by a genetic switch, play a more important role in the 
protection from antimicrobial agents than the external resistance 
provided by the exopolysaccharide matrix.
[53]
 
 Bacteria embedded in biofilm have reduced growth rates, which in 
turn minimizes the rate at which antimicrobial agents are taken 
into the cell and therefore affect inactivation kinetics.
 [53]
  
 Antibiotic degrading enzymes such as β-lactamase may also be 
immobilized in the EPS matrix, so that the incoming antibiotic 
molecules can be inactivated effectively. 
[3]
 
 The cell-wall protein composition of bacteria in biofilms is 
altered by up to 40% from that of its planktonic counterparts.
 [54]
 
Antibiotic targets may even disappear or membranes of the 
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biofilm bacteria might be better equipped to pump out the 
antibiotics before they produce any damage. 
 Bacteria within a biofilm can sense the external environment, 
communicate with each other and transfer genetic information and 
plasmids within biofilm which provides a mechanism for selecting 
and promoting the spread of bacterial resistance to antimicrobial 
agents.
[49]
 
VARIOUS METHODS OF COLLECTION OF URINE SPECIMEN      
Prevention of contamination by normal vaginal, perineal, and 
anterior urethral flora is the most important consideration for collection 
of a clinically relevant urine specimen. 
Clean-catch midstream urine (CCMU) 
The least invasive procedure, the clean-catch midstream urine 
specimen collection, must be performed carefully for optimal results, 
especially in females. Good patient education is essential.
 [15]
  
Straight catheterized urine 
Although this method is slightly more invasive than CCMU, 
urinary catheterization provides a method for the collection of 
uncontaminated urine from the bladder.
 [15] 
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Suprapubic bladder aspiration
 
Following proper skin preparation, urine is withdrawn directly 
into a syringe through a percutaneously inserted needle, thereby 
ensuring a contamination-free specimen. The bladder must be full before 
performing the procedure. This collection technique may be indicated 
when urine sample is difficult to obtain such as in pediatric patients.
 [15]
  
      Indwelling catheter 
Strict aseptic precautions like wearing gloves should be followed 
while collecting specimen from indwelling catheter.  The catheter tubing 
should be clamped off above the port to allow the collection of freshly 
voided urine. The catheter port or wall of the tubing should then be 
cleaned vigorously with 70% ethanol, and urine aspirated via a needle 
and syringe; the integrity of the closed drainage system must be 
maintained to prevent the introduction of organisms into the bladder. 
[15]
 
      Specimen transport 
Urine is an excellent supportive medium for growth of most 
bacteria, so must be transported to the laboratory and processed within 
2hours of collection. If a delay occurs specimens may be refrigerated for 
up to 24 hours. Urine transport tubes containing boric acid preservative 
has to be used to stabilize the bacterial population at room temperature 
for 24 hours if refrigeration is not available.
 [55]
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SCREENING PROCEDURES FOR URINE SPECIMEN 
Direct Gram stain 
A Gram stain of urine is an easy, inexpensive means to provide 
immediate information as to the nature of the infecting organism to 
guide empiric therapy. The presence of 1or 2 bacteria of similar 
morphotype in each oil immersion field (100X objective) correlates with 
a count of 100,000 or greater by culture.
 [55]
 The Gram stain should not 
be relied on for detecting polymorphonuclear leukocytes in urine 
because leukocytes deteriorate quickly in urine that is not processed 
immediately or not adequately preserved. 
Pyuria 
 Patients with more than 400,000 polymorphonuclear neutrophils 
(PMNs) excreted into the urine per hour are likely to be infected, and 
the presence of more than 8 PMNs/mm
3
 correlates well with this 
excretion rate and with infection.
 [15] 
Tests for bacterial products 
Dipsticks that detect both Leucocyte esterase an enzyme produced 
by polymorphonuclear neutrophils and Nitrite produced as a result of 
bacterial nitrate reductase acting on nitrate in urine are available. The 
test is rapid, inexpensive and simple to perform. 
[55] 
 
 
 27 
Catalase test 
The commercially available uriscreen is a rapid urine-screening 
system based on the detection of catalase present in most bacterial 
species commonly causing UTIs except for Streptococcus spp., and 
Enterococcus spp. 30% (V/V) hydrogen peroxide is added to the urine, 
and the solution is mixed gently. The formation of bubbles above the 
liquid surface is interpreted as a positive test.
 [15] 
URINE CULTURE 
Routine urine cultures should be plated using calibrated 
bacteriological loops for the semiquantitative method. This method has 
the advantage of providing information regarding the number of CFU/ml 
of urine, as well as providing isolated colonies for identification and 
antibiotic susceptibility testing. MacConkey agar plate and 5% sheep 
blood agar plate are used to detect the growth of most  Gram negative 
bacilli, Staphylococcus spp., Streptococcus spp., Enterococcus spp., and 
fungi like Candida spp. 
INTERPRETATION OF URINE CULTURE RESULTS 
The following criteria is used for urine specimens obtained via  
suprapubic aspiration or straight catheterization, specimens obtained in 
the operating room, and urine specimens obtained from patients 
receiving antimicrobial therapy which have a low probability of  
contamination.
 [56]
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Types of Colonies 
Isolated 
Quantitation 
CFU/ml 
Interpretation 
1 < 10
2 
Probable contaminant 
1 ≥102 Significant isolate 
2 < 10
2
 for 
each 
Probable contaminants 
2 ≥102 for each Significant isolates 
2 ≥102 for 1 Significant isolate and 
contaminant 
≥3 ≥102 for 1 Significant isolate and 
contaminants 
≥3 ≥105 for each Probable contaminants 
The following criteria is used for urine specimens obtained via 
clean catch technique, from indwelling catheters (urinary or 
suprapubic), or from nephrostomy tubes, ureterostomy tubes, or ileal 
loops which have a high probability of contamination.
 [56] 
Types  of colonies 
isolated 
Quantitation 
CFU/ml 
Interpretation 
1 < 10
2 
Probable contaminant 
1 ≥102 Significant isolate 
2 ≥102 for each Significant isolates 
2 ≥102 for 1 Significant isolate and 
contaminant 
2 < 10
2
 for each Probable contaminants 
≥3 ≥102 for 1 Significant isolate and 
contaminants 
≥3 ≥102 for each Probable contaminants 
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DIAGNOSIS OF MICROBIAL URETERAL STENT 
COLONIZATION  
The various studies analyzing Microbial ureteral stent 
colonization (MUSC) used sonication, qualitative broth culture and 
Maki‟s semiquantitative roll-plate technique.  [57- 60] Maki‟s roll- plate 
technique is the international reference and most widely used technique for the 
diagnosis of catheter-related blood stream infections (CRBSI).
 [61]
 Since roll-
plate technique is not inferior to sonication in the detection of CRBSI, it 
is also applied for the diagnosis of MUSC.
 [62]
  
Maki‟s roll-plate technique has the advantages of a higher 
detection rate of microorganisms and cost-efficiency. It is time saving, 
requires only 2 minutes when compared with 10 minutes for sonication 
and there is no need for additional sophisticated technical equipment 
(i.e. ultrasound bath, hydrophone).
 [60] 
METHODS FOR BIOFILM DETECTION 
I. Phenotypic methods 
 The Microtitre plate method – The wells of the microtitre plates 
are inoculated with a bacterial suspension along with positive and 
negative controls and these are incubated for 24 to 48 hours. 
Planktonic cells are removed by washing with phosphate buffered 
saline. Biofilms are fixed with 2% sodium acetate and are stained 
with 0.1% crystal violet. The excess dye is washed away with 
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deionised water. 95% ethanol is added to solublize the dye and the 
optical densities of the stained biofilms are obtained 
spectrophotometrically.
[63]
 
 The Tube method – 10 ml of Trypticase soy broth with 1% 
glucose is inoculated with a loopful of test organisms, along with 
positive and negative controls. The broths are incubated 
aerobically at 37°C for 24 to 48 hours. The culture supernatants 
are decanted and the tubes are washed with phosphate buffered 
saline. The tubes are dried and are stained with 0.1% crystal 
violet. The excess stain is washed away with deionised water. The 
tubes are dried in an inverted position. Biofilm formation is 
considered positive when a visible film lined the wall and bottom 
of the tube.
 [64]
 
 The Congo red agar method – The Congo red stain is prepared 
as a concentrated aqueous solution and is autoclaved at 121°C for 
15 minutes at 15psi. This is added to autoclaved Brain heart 
infusion agar with 4% glucose at 55°C. The plates are inoculated 
with the test organisms along with positive and negat ive controls 
and are incubated at 37°C for 24 to 48 hours aerobically. Black 
colonies with a dry crystalline consistency indicate biofilm 
production.
 [65]
 .The tissue culture plate is better than other 
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methods since it is easy to perform and helps to assess biofilms, 
both qualitatively and quantitatively. 
[66]
 
II. Genetic assays for clinical diagnostics and epidemiology  
Various genetic methods that are used for detection of biofilms 
are Pulsed field gel electrophoresis (PFGE), Polymerase chain reaction 
(PCR), Fluorescence in situ hybridization (FISH), Ribotyping, High-
resolution melting analysis, DNA sequencing, and DNA arrays.
 [67] 
 
III. Microscopy in research and explanted device analysis  
Microscopy is a commonly used tool for analyzing structural 
details of biofilms in vitro.
 [68]
 
 Confocal laser scanning microscopy (CLSM) with fluorescent 
stains, antibodies, and lectins is ideal to characterize biofilms up 
to 60 μm thickness.  [67] 
 Scanning electron microscopy (SEM) helps to study the real 
physical change in morphology, density, and substructures of 
biofilms. 
[67]
 
 Atomic force microscopy (AFM) is a useful tool for measuring 
physical properties of biofilms, for monitoring bacterial adhesion 
on different surfaces, interactions between cells, and measuring 
the strength of adhesion by bacterial adhesins and other 
macromolecules. 
[67]
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 Magnetic resonance imaging and scanning transmission X-ray 
microscopy are other methods used for successful assessment of 
biofilms 
[69]
 
NEW STENT DESIGNS 
 Dual durometer stents involve a transition from a firm biomaterial 
at the renal end to a soft biomaterial or a fine loop at the bladder 
end, to facilitate stent placement, reduce migration and minimize 
patient discomfort due to bladder irritation.
 [20, 70]
 
 Thermoexpandable stents are nickel-titanium alloy stents, used 
where long-term stenting is needed such as in malignant ureteric 
strictures e.g., Wall stent or Memocath 051
TM
.
 [20]
 The stent 
(unexpanded state) is placed in the ureter after prior dilatation and 
later expanded by injecting sterile heated water at 50
0
C. The shaft 
diameter is 9F while the proximal end expands to a calibre of 17F.  
 Magnetip is a magnetic-material-tipped ureteral stent that can be 
retrieved without the need for cystoscopy using a magnet on a 
special retrival catheter. 
[70]
 
 Percuflex Helical ureteral stent has a spiral-cut along the entire 
length of the straight portion of the stent, designed to conform 
readily to the shape of the ureter to improve patient comfort.
 [20,70, 71]
 
 33 
 Biodegradable stents: After placement, stents made of 
bioabsorbable polymeric materials e.g., Poly-L-lactide-co-
glycolide (PLGA), are gradually biodegraded into tissue-
compatible compounds that are absorbed and replaced by healing 
tissue, thereby eliminating the need for cystoscopic removal and 
the problem of forgotten or neglected stents. 
[70, 71]
 
STENT COATINGS  
Stent coatings are a part of stent evolution with the most 
significant development and promising future prospects.  
1. Hydrophilic stent coatings 
      Ureteral stents coated with hydrophilic compounds such as Hydrogel 
and Polyvinylpyrrolidone (PVP) have excellent lubricant properties and 
provides smooth and non –adhesive implant surface, which prevents 
conditioning film formation and bacterial adhesion.
 [72, 73]
    
2. Heparin  
Heparin is a highly sulfated glycosaminoglycan, with the highest 
negative charge density amongst all known biologic molecules.
 
Heparin-
coated polymeric stents have been shown to provide the stent with an 
antiadhesive surface that reduces biofilm formation and concomitant 
stent encrustation.
 [71]  
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3. Oxalate-degrading enzymes 
 Oxalyl coenzyme A decarboxylase (OXC) and formyl coenzyme 
A transferase (FRC) are oxalate-degrading enzymes derived from 
anaerobic bacterium Oxalobacter formigenes which when coated on to 
biomaterials were found to reduce encrustation. 
[74] 
4. Diamond-like carbon coating 
Stents coated with a plasma deposited diamond like amorphous 
carbon material are characterized by excellent biocompatibility and were 
found to decrease stent friction, encrustation tendencies and biofilm 
formation. 
[75] 
5. Drug eluting stents 
Ureteral stents can be loaded with pharmacological agents that 
continuously release over time to act locally on the urinary tissue.Drug 
eluting stents that have been developed are Rifampin –soaked ureteral 
stents, Triclosan coated stents, Ciprofloxacin /N-acetylcysteine 
impregnated ureteral catheters, Silver nitrate and Ofloxacin-blended 
copolymer-coated urospiral stents, Ketorolac loaded stents and 
Paclitaxel eluting metal stents. Drug eluting stents have been found 
effective in preventing biofilm formation and stent encrustation. 
[76-81]
   
6. Biomimetic and Biocovered stents 
The development of tissue-engineered stents would be 
advantageous because of its inherent biocompatibility. Amiel et al have 
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demonstrated the feasibility of using cartilaginous stents created in vitro 
and in vivo using chondrocyte-seeded polymer matrices.
 [82]
  
TREATMENT OF UTI 
 Trimethoprim-sulfamethoxazole has been recommended as the 
first line of treatment for acute cystitis. The use of this drug is 
considered appropriate in regions with resistance rates not 
exceeding 20%.
[83]
 
 Nitrofurantoin remains highly active against Escherichia coli. [83] 
 Fluoroquinolones commonly used for UTI include Ofloxacin, 
Ciprofloxacin and Levofloxacin.
 [83]
 
 Combinations of a β lactam + β lactamase inhibitors    like 
(Ampicillin+ sulbactum, Piperacillin+ Tazobactum) or Imipenem 
–Cilastin can be used in patients with more complicated histories, 
previous episodes of pyelonephritis or recent urinary tract 
manipulations. The treatment of such patients should be guided by 
urine culture results.
 [83]
  
 Fluconazole which achieves high levels in urine is the first line 
regime for Candida infections of the urinary tract. For Candida 
isolates resistant to Fluconazole, oral Fluocytosine or parenteral 
Amphotericin B can be given.
 [83]
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MATERIALS AND METHODS 
 Ethical consideration 
Approval from the Institutional Ethics committee was obtained 
before commencement of the study. Informed consent was obtained from 
patients who satisfied the inclusion criteria.  
Study design        
Cross sectional study 
Study period 
Period of study was from November 2014 to August 2015 
Sample size 
100 patients 
Study population 
100 patients admitted under the Department of Urology, Rajiv 
Gandhi Government General Hospital, Chennai and treated with Double-
J ureteral stent placement for ureteral obstruction and who satisfied the 
inclusion criteria were enrolled and evaluated in this study.  
Study setting 
The present study was carried out in the Institute of Microbiology, 
Madras Medical College, in association with Department of Urology, 
RGGGH , Chennai.    
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Inclusion criteria 
 Male and female patients of more than 18 years of age.  
 Patients who undergo Double-J ureteral stent placement for 
ureteral obstruction during the study period. 
 Patients with negative urine culture before Double-J ureteral stent 
placement. 
Exclusion criteria 
 Patients less than 18 years 
 Patients currently on antibiotic treatment 
 Patients with malignancy of genitourinary tract  
 Patients with renal transplantation 
 Patients with coagulation disorders 
 Pregnant women 
Collection of data 
Data was collected from patients who satisfied the inclusion 
criteria. A detailed history regarding name, age, gender, presenting 
complaints, past history of any co-morbid illness, recent antibiotic 
treatment and details of surgery were recorded before collecting the 
samples. Vital signs were recorded.  
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SPECIMEN COLLECTION AND TRANSPORT 
 Collection of Urine Sample:  
   Two urine samples were collected from each patient, one before 
Double-J ureteral stent placement and another before stent removal.  
Urine samples from patients satisfying the inclusion criteria were 
collected in a sterile, wide mouthed disposable container under aseptic 
precautions. Male patients were instructed to thoroughly cleanse and 
then retract glans penis before voiding and then to collect the clean 
catch midstream urine sample. Female patients were instructed to wash 
the genital area with soap and water and collect the clean catch 
midstream urine sample keeping the labial folds apart with two fingers. 
Urine samples were transported to the microbiological laboratory within 
30 minutes of collection.  
 Double- J ureteral stent proximal tip collection  
Double-J ureteral stents were removed aseptically from patients 
under local anaesthesia with the help of a rigid cystoscope. Under  
sterile precautions, about 3- 5 cm of the proximal tip of the Double-J 
ureteral stent was collected in a sterile plastic screw-capped container 
and processed in the microbiological laboratory within 6 hours of 
collection . 
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SPECIMEN PROCESSING 
 Direct Gram stain 
 A smear was prepared from a drop of well mixed uncentrifuged 
urine on a new glass slide, air dried, heat fixed and stained by Gram 
stain technique. The smear was first examined with the 40X objective 
and then with oil immersion objective for the presence of epithelial 
cells, pus cells, and bacteria. The presence of 1or more bacteria of 
similar morphology in each oil immersion field correlates with a count 
of 100,000 or greater by culture. 
 10% potassium hydroxide (KOH) preparation 
A loopful of urine sample was placed on a clean glass slide and a 
drop of 10% KOH solution was added to it and mixed well. A coverslip 
was placed over the preparation. The slide was examined carefully first 
under 10X objective and then with 40X objective to detect hyphal 
elements, budding yeast cells, spores or conidia.  
 Semiquantitative urine culture 
The collected urine sample was inoculated onto, MacConkey agar 
plate, 5% sheep Blood agar plate and  two Sabouraud dextrose agar 
(SDA)slopes. 
A calibrated bacteriological loop made of nichrome wire (2mm) 
that delivers a volume of 0.001 ml of urine was flamed and allowed to 
cool. The loop was inserted vertically into the urine sample mixed well, 
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without touching the sides of the container and the loopful of sample 
was spread over the surface of the MacConkey agar plate, by streaking 
from top to bottom in a vertical line and again from top to bottom 
perpendicular to this line in a back and forth fashion. Without reflaming, 
the loop was inserted vertically into the urine again for transfer of a 
loopful to the 5% sheep blood agar plate. The MacConkey agar plates 
were incubated at 35° to 37°C aerobically for 24 hours and blood agar 
plates were incubated at 35° to 37°C in candle jar for 24 hours. One 
SDA slope was incubated at 25°C and another at 37°C aerobically and 
examined for growth twice weekly in first week and once a week for 
next four weeks. 
 Maki’s roll-plate semiquantitative culture method for Double -J 
ureteral stent proximal tip  
The Maki‟s roll-plate method was performed by rolling the 
external surface of the ureteral stent tip back and forth on the surface of 
a 5 % sheep blood agar plate at least three times and then incubating the 
plate aerobically in candle jar at 37°C for 24 hours, after which the 
number of colony-forming units (CFU) was quantitated.
 [60] 
INTERPRETATION OF CULTURE RESULTS 
After 24 hours of incubation, MacConkey and 5% sheep blood 
agar plates were observed for growth, colony count and colony 
morphology. Gram stain was done to confirm the colony morphology.  
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 The number of colony forming units was calculated by the 
following formula: Number of colony forming units = colony 
count × urine dilution factor. Dilution factor is 1000 when 4mm 
loop which delivers 0.01 ml sample was used, or 100 when 2mm 
loop which delivers 0.001 ml sample was used. Significant 
bacteriuria was defined as a count of more than 10
5
 colony 
forming units (CFU) /ml of urine.  
 Maki‟s roll-plate Semiquantitative culture of Double -J ureteral 
stent tip was considered significant when ≥15 CFU were seen.  
IDENTIFICATION OF ISOLATES 
 If colony morphology on MacConkey agar and Blood agar plates 
were suggestive of Gram negative bacilli, preliminary tests such 
as Gram staining, hanging drop for motility, Catalase and Oxidase 
tests, were performed. Catalase positive, Oxidase negative, Gram 
negative bacilli were identified as members of Enterobacteriaceae. 
The isolates were identified up to the species level by means of 
biochemical tests such as Nitrate reduction test, Hugh-Leifson‟s 
Oxidation fermentation test, Indole test, Methyl red test, Voges 
Proskauer test, Triple sugar iron agar, Simmon‟s citrate utilization 
test, Christensen‟s Urease test, Phenylalanine deaminase test, 
Lysine decarboxylase, Ornithine Decarboxylase and Arginine 
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dihydrolase test and 1% Sugar fermentation tests with Glucose, 
Sucrose, Lactose, Maltose and Mannitol.
[84]
 
 Gram negative bacilli, which were motile, catalase and oxidase 
positive, with alkaline slant and alkaline butt in Triple sugar iron 
agar and production of bluish green diffusible pigment on Muller 
Hinton agar plate were identified as Pseudomonas species.
[85]
 
 If Gram negative coccobacilli, which were nonmotile, Catalase 
positive and Oxidase negative additional tests such as growth at 
44°C, 10% OF lactose utilization test and Malonate utilization test 
were done to identify Acinetobacter species.
[86]
 
 If shiny, white opaque colonies with a zone of hemolysis around 
them were seen in 5% sheep blood agar plate and Gram staining 
showed Gram positive cocci in clusters, colonies were subjected 
to catalase test, coagulase test – Slide and Tube method, modified 
oxidase test, urease test, Hugh-Leifson‟s Oxidation fermentation 
test, mannitol fermentation test, Phenolphthalein phosphatase test 
and Gelatin liquefaction to identify Staphylococcus aureus.
[87]
 
 If Gram positive cocci in clusters that were catalase positive and 
coagulase negative were identified, the following additional tests 
were done for speciation of Coagulase Negative Staphylococci 
(CoNS).
[87]
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 Carbohydrate fermentation tests using Lactose, Mannitol, 
Mannose, Xylose, Trehalose. 
 Nitrate reduction test 
 Ornithine decarboxylase test 
 Differential disc diffusion test with Novobiocin(5µg) and 
Polymyxin B 300 units.  
 If pin-point magenta colonies were seen in MacConkey agar and 
Gram staining showed Gram positive oval cocci in pairs, which 
were catalase negative the following tests were done.
[88]
 
 Heat tolerance test at 60°C 
 Growth in 6.5% Sodium chloride 
 Bile esculin hydrolysis 
 Arginine dihydrolase test 
 Carbohydration fermentation tests using Mannitol, Sorbitol, 
Arabinose, Raffinose 
 PYR(Pyrrolidonyl-beta-naphthylamide) test 
 Colonies seen in SDA slopes were subjected to Gram Staining and 
Lactophenol cotton blue mount. Creamy white, dry colonies with 
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Gram positive budding yeast cells and pseudohyphae in Gram 
Stain were seen, the following tests were done.  
 Germ tube test 
 Growth in Candida CHROM Agar 
Yeast colonies were streaked onto Candida CHROM Agar and 
incubated at 37°C for 72 hrs. The various coloured colonies produced by 
different species of Candida on CHROM Agar were noted and species 
were identified accordingly.
 [89] 
         Colour of Candida colonies on Candida CHROM agar 
Candida spp. Colour on Candida CHROM Agar 
Candida albicans Light- green 
Candida dublinensis Dark –green 
Candida glabrata Pink to purple 
Candida krusei Pink 
Candida parapsilosis Cream to pale pink 
Candida tropicalis Metallic Blue  
 Corn meal agar plate (Dalmau plate) 
With a sterile straight wire, a heavy inoculum of the yeast was 
streaked across the corn meal agar plate in three parallel lines. Cover 
slip was kept on it in such a way that the streak lines project beyond the 
cover slip. Plates were incubated at 22°C to 26°C in dark for 3 days . The 
edge of the cover slip was examined under the microscope by placing 
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the agar plate on the stage and observing under the low and high power 
objectives. 
Corn Meal Agar Morphology 
Species 
Identification 
Pseudohyphae with terminal chlamydospores; 
clusters of blastoconidia at septa 
Candida albicans 
Candida 
dublinensis 
Abundant Pseudohyphae, pine forest arrangement,  
blastoconidia formed at  or in between septa 
Candida 
tropicalis 
Elongated yeasts, Abundant Pseudohyphae, 
(matchstick- like appearance) 
Candida krusei  
Blastoconidia along curved pseudohyphae; giant 
mycelia cells 
Candida 
parapsilosis  
No pseudohyphae; small cells; terminal budding Candida glabrata 
 Sugar fermentation test using 2% sugars – Glucose, Sucrose, 
Lactose, Maltose, Galactose, Trehalose 
 Sugar Assimilation test. 
 Heavy inoculum of yeast suspension was prepared in 2ml of yeast 
nitrogen base and added to 18 ml of molten yeast nitrogen base 
yeast nitrogen base agar and mixed well. Various carbohydrate 
impregnated discs namely Glucose, Sucrose, Lactose, Maltose, 
Galactose, Trehalose, Xylose, Raffinose, Celibiose, Ionositol, 
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Dulcitol were placed with a sterile forceps 30mm apart and 
incubated at 30°C for 24-48 hours.  
 Growth around the carbohydrate disc was interpreted as positive 
for assimilation of the particular sugar. 
     ANTIBIOTIC SUSCEPTIBILITY TESTING 
         Antibiotic Susceptibility testing of the isolated organisms was done on 
Muller Hinton agar plates by Kirby Bauer disc diffusion method as per CLSI 
document M 100-S24.
 [90] 
The antibiotic discs were obtained from HiMedia 
Laboratories Private limited, Mumbai. 
Inoculum preparation 
 Three to five well isolated colonies were selected from the 5% 
sheep Blood agar plate, top of each colony was touched with a 
bacteriological loop and inoculated into 4-5 ml of nutrient broth. 
The broth culture was incubated at 35°C for 2 hours. The turbidity 
of broth culture was adjusted with nutrient broth to obtain 
turbidity optically comparable to that of the 0.5 McFarland 
standard.  
 A sterile cotton swab was dipped into the adjusted suspension. 
The dried surface of a Muller Hinton agar plate was inoculated by 
streaking the swab over the entire sterile agar surface. Five 
antibiotic discs were placed per plate 24 mm apart from center to 
center and incubated aerobically for 24hours at 37°C. 
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 The diameter of the zone of inhibition was measured and recorded 
in millimeters and was then compared with zone diameter 
interpretive standards chart of the CLSI document M 100-S24.
 [90]
 
The quality control for antimicrobial susceptibility testing was 
done with the following standard strains; Escherichia coli ATCC 
25922, Staphylococcus aureus ATCC 25923, Enterococcus 
faecalis ATCC 29212, Pseudomonas aeruginosa ATCC 27853. 
Zone diameter interpretive standards for Gram negative bacilli 
Antimicrobial 
Agent 
Disc 
content 
µg 
Gram 
Negative 
Bacilli 
Zone Diameter 
Interpretive Criteria 
(nearest whole mm) 
Sensi-
tive 
Inter-
mediate 
Resis-
tant 
Ampicillin  10 Escherichia coli ≥ 17 14-16 ≤ 13 
Amikacin 10 Enterobacteriaceae 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumanii 
≥ 17 15-16 ≤ 14 
Gentamicin 10 Enterobacteriaceae 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumanii 
≥15 13-14 ≤ 12 
Trimethoprim/ 
Sulfamethoxazole 
1.25/ 
23.75 
Enterobacteriaceae 
and Acinetobacter 
baumanii 
≥16 11-15 ≤ 10 
Ciprofloxacin 5 Enterobacteriaceae 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumanii 
≥21 16-20 ≤ 15 
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Antimicrobial 
Agent 
Disc 
content 
µg 
Gram 
Negative 
Bacilli 
Zone Diameter 
Interpretive Criteria 
(nearest whole mm) 
Sensi-
tive 
Inter-
mediate 
Resis-
tant 
Cefotaxime 
 
30 
 
Enterobacteriaceae ≥26 23-25 ≤ 22 
Acinetobacter 
baumanii 
≥23 15-22 ≤ 14 
Ceftazidime 30 Enterobacteriaceae ≥21 18-20 ≤ 17 
Pseudomonas 
aeruginosa and 
Acinetobacter 
baumanii 
≥18 15-17 ≤ 14 
Tetracycline 30 Enterobacteriaceae ≥15 12-14 ≤ 11 
Imipenem 10 Enterobacteriaceae ≥23 20-22 ≤ 19 
Pseudomonas 
aeruginosa 
≥19 16-18 ≤ 15 
Acinetobacter 
baumanii 
≥22 19-21 ≤ 18 
Piperacillin/ 
Tazobactum 
100/ 
10 
Enterobacteriaceae 
and Acinetobacter 
baumanii 
≥21 18-20 ≤ 17 
Pseudomonas 
aeruginosa 
≥21 15-20 ≤ 14 
Ofloxacin 5 Enterobacteriaceae 
Pseudomonas 
aeruginosa 
≥16 13-15 ≤ 12 
Norfloxacin 5 Enterobacteriaceae 
Pseudomonas 
aeruginosa 
≥17 13-16 ≤ 12 
Nitrofurantoin 300 Enterobacteriaceae ≥17 15-16 ≤ 14 
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Zone diameter interpretive standards for Staphylococcus spp. 
Antimicrobial 
Agent 
Disc 
content 
 
Zone Diameter Interpretive Criteria 
(nearest whole mm) 
Sensitive Intermediate Resistant 
Penicillin 10 units ≥ 29 - ≤ 28 
Trimethoprim/ 
Sulfamethoxazole 
1.25/23.75 
µg 
≥16 11-15 ≤ 10 
Linezolid 30 µg ≥23 - ≤ 20 
Tetracycline 30 µg  ≥19 15-18 ≤ 14 
Ciprofloxacin 5 µg ≥21 16-20 ≤ 15 
Norfloxacin 5 µg ≥17 13-16 ≤ 12 
Nitrofurantoin 300 µg ≥17 15-16 ≤ 14 
Zone Diameter Interpretive Standards for Enterococcus spp. 
Antimicrobial 
Agent 
Disc content 
 
Zone Diameter Interpretive Criteria 
(nearest whole mm) 
Sensitive Intermediate Resistant 
Ampicillin 10 µg ≥ 17 - ≤ 16 
Penicillin 10 units ≥ 15 - ≤ 14 
Linezolid 30 µg ≥23 21-22 ≤ 20 
Vancomycin 30 µg ≥17 15-16 ≤ 14 
High level 
Gentamicin 
120 µg ≥10 7-9 ≤ 6 
Ciprofloxacin 5 µg ≥21 16-20 ≤ 15 
Norfloxacin 5 µg ≥17 13-16 ≤ 12 
Tetracycline 30 µg ≥19 15-18 ≤ 14 
Nitrofurantoin 300 µg ≥17 15-16 ≤ 14 
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ANTIFUNGAL SUSCEPTIBILITY TESTING 
 Disc diffusion testing of each isolate was done with Fluconazole 
and Voriconazole as per CLSI document M44-A.
 [91]
 Mueller 
Hinton agar plates supplemented with 2% glucose and 0.5 μg/ml 
methylene blue was used.  
 Inoculum was prepared by picking 5 distinct colonies of 1mm 
diameter from a 24 hour old culture of Candida spp. and 
suspended in 5ml of sterile 0.85% saline. The suspension was 
vortexed for 15 min and the turbidity was adjusted to 0.5 
McFarland standards to yield a yeast stock of 1×10
6 
to 5×10
6 
cell/ml. The cell suspension was inoculated on to the agar plate by 
streaking with a swab over the entire agar surface.  
 Antifungal discs were placed on the inoculated agar plates and 
incubated at 35°C for 48 hours. Zone diameter is measured to the 
nearest whole millimeter at the point where there was prominent 
reduction in growth.  
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Zone diameter interpretive standards for Candida species. 
Antifungal 
Agent 
Disc 
content 
µg 
Zone Diameter Interpretive 
Criteria (nearest whole mm) 
Sensitive Intermediate Resistant 
Fluconazole 25 ≥ 17 14-16 ≤ 13 
Voriconazole 1 ≥ 17 15-16 ≤ 14 
The following Control strains were used for antisusceptibility 
testing for yeasts; Candida albicans ATCC 90028 and Candida 
parapsilosis ATCC 22019. 
Determination of Minimum Inhibitory concentration (MIC) for 
Vancomycin for Methicillin Resistant Staphylococcus spp. by Broth 
Macrodilution Method 
Preparation of antibiotic stock solution
 [92] 
     V x C 
Formula:    W = 1000 x  --------- 
         P 
Where P = potency 950 μg/mg, 
 V = volume required 10 mL,  
C = final concentration of solution 1024 μg/ml. 
W = weight of antibiotic in mg to be dissolved in volume V (mL).  
Inoculum preparation 
 Four to five morphologically similar colonies of the test organism 
from a 24 hour old culture were picked up with a sterile 
bacteriological loop and suspended in nutrient broth and 
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incubated at 35°±2°C. Then the cell suspension was diluted to 
1:100 and turbidity was adjusted to 0.5 McFarland standard.  
 Same procedure was followed for the control organism 
Enterococcus faecalis ATCC 29212. 
Procedure 
 The antibiotic stock solution was prepared by adding required 
amount of Vancomycin drug substance to 10 ml of 0.85% saline.      
 Two rows of 12×75 mm tubes each containing 13 test tubes, one 
row for the test organism and other row for the control organism 
were arranged. 1 ml of Muller Hinton broth  was added to each 
tube which were labelled as follows: 512, 256, 128, 64, 32, 16, 8, 
4, 2, 1, 0.5, 0.25, 0.125 μg/ml.  
 From the stock solution 1ml of antibiotic solution was added to 
tube labelled 512 μg/ml with a micropipette then 1ml from 512 
μg/ml tube to 256 μg/ml tube, similarly serial dilution was done 
till the last tube labelled 0.125 μg/ml and 1ml was discarded from 
the last tube. 
 1ml of the 1:100 dilution of the inoculum of test organism was 
added to each test tube in one set of tubes and control organism 
was added to another set of tubes and incubated aerobically at 35°- 
37°C for 18-24 hours. 
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 Growth control and drug control tubes were included for s terility 
check. 
 The MIC end point was read as the lowest concentration of the 
antibiotic at which there was no visible growth.  
 The MIC of control strain was observed, which was within 
sensitive range, hence the test was considered to be valid.  
Minimum Inhibitory concentration (MIC) interpretive standards of 
Vancomycin for Staphylococcus spp. 
Organism 
MIC Interpretive Criteria (µg/ml) 
Sensitive Intermediate Resistant 
Staphylococcus aureus ≤ 2 4-8 ≥  16 
Staphylococcus epidermidis ≤ 4 8-16 ≥  32 
Determination of Minimum inhibitory concentration (MIC) of 
Meropenem by Broth Macrodilution Method for Imipenem resistant 
Gram negative Bacilli  
Preparation of antibiotic stock solution
 [92] 
     V x C 
Formula:    W = 1000 x  --------- 
         P 
Where P = potency 750 μg/mg, 
 V = volume required 10 mL,  
C = final concentration of solution 1024 mg/L, and  
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W = weight of antibiotic in mg to be dissolved in volume V (mL).  
 The required amount of drug was calculated and dissolved in 10ml 
of 0.85% saline. 
 Same procedure was followed as for Vancomycin MIC and the 
control organism was Escherichia coli ATCC 25922. 
Minimum Inhibitory concentration (MIC) interpretive standards of 
Meropenem for Gram negative bacilli 
Organism 
MIC Interpretive Criteria (µg/ml) 
Sensitive Intermediate Resistant 
Enterobacteriaceae ≤ 1 2 ≥  4 
Pseudomonas aeruginosa ≤ 2 4 ≥  8 
Determination of Minimum inhibitory concentration (MIC) of 
Amphotericin B by Broth Microdilution Method for Yeast  
Preparation of antifungal stock solution 
[93]
 
     V x C 
Formula:    W = 1000 x  --------- 
         P 
Where P = potency 750 μg/mg,  
 V = volume required 10 mL,  
C = final concentration of solution 1600µg/ml, and  
W = weight of antibiotic in mg to be dissolved in volume V (mL).  
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 Broth microdilution method for yeasts was performed as per the 
CLSI guidelines M27-A3. [93] Dimethyl sulfoxide (DMSO) was 
used as solvent and RPMI 1640 (with glutamine, without 
bicarbonate and phenol red as indicator) was used as broth 
medium. The concentration of Amphotericin B tested was in the 
range of 0.0313 to 16 µg/ml. 
Inoculum preparation 
 Five morphologically similar colonies of the Candida species 
from a 24 hour old culture were picked up using a sterile 
bacteriological loop and suspended in 5 ml of 0.85% saline and 
incubated at 35°±2°C. The cell suspension was vortexed for 15 
seconds and cell density was adjusted with a spectrophotometer 
by adding sufficient sterile 0.85% saline to increase the 
transmittance equivalent to that produced by a 0.5 McFarland 
standard. 
 A working suspension was made by 1:100 dilution followed by a 
1:20 dilution of the stock suspension with RPMI 1640 broth 
medium which results in 5×10
2
 to 2.5×10
3
 cells/ml. 
 Same procedure was followed for the control organism Candida 
albicans ATCC 90028. 
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Procedure 
 The broth microdilution was performed by using sterile disposable 
U shaped 96 well microdilution plates. 100 µl of varying drug 
concentrations were dispensed in each row from 1to 10 wells.  
 11th column of microdilution plate was the growth control with 100 µl 
of sterile drug free medium and inoculated with the corresponding 
inoculum suspension. 12th column of microdilution plate was the drug 
control with 100 µl of sterile drug free medium and 100 µl drug.  
 The microdilution plates were incubated for 24 hours at 35°C. 
After 24 hours the microdilution were scored with the aid of a 
reading mirror. The growth in each well was compared with that 
of the growth control well.  
 The MIC was interpreted as the well with lowest concentration of 
drug with no visible growth. 
 If the MIC is ≥ 1 µg/ml for a Candida spp. then it is likely to be 
resistant to Amphotericin B. 
DETECTION OF BETA-LACTAMASE PRODUCTION IN GRAM 
NEGATIVE BACILLI 
 Screening test for Extended-Spectrum Beta-Lactamases 
(ESBL’s) 
         Each isolate was screened for the ESBL production against 
Cefotaxime (30μg) and Ceftazidime (30μg) discs by disc diffusion 
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method. Isolates with zone size of ≤ 27 mm for Cefotaxime or ≤ 22 mm 
for Ceftazidime were suspected to be ESBL producer.
[90]
 
 Phenotypic Confirmatory test for ESBL 
All isolates suspected to be ESBL producers in the screening test 
were further confirmed as per the CLSI guidelines by the disc 
potentiation test by using Ceftazidime (30μg) and Ceftazidime -
clavulanic acid (30/10μg) discs and Cefotaxime (30μg) and Cefotaxime -
clavulanic acid (30/10μg) discs. [90] 
A ≥ 5-mm increase in zone diameter for either antimicrobial agent tested 
in combination with clavulanic acid versus the zone diameter of the 
agent when tested alone signified a positive ESBL. Escherichia coli 
ATCC 25922 was used as the quality control strain.
[90]
 
Detection of the Metallo- β- lactamases (MBL’s)  
 The isolates which were resistant to Imipenem were suspected of 
metallo-β lactamase production. 
 The metallo-β lactamase production was detected by the 
Imipenem – Ethylene diamine tetraacetic acid (IPM+ EDTA) 
double disc synergy test.
[94]
  
 Suspected isolate adjusted to 0.5 McFarland standard was 
swabbed onto a plate of Mueller Hinton agar. 10μg Imipenem 
(IPM) disc and a IPM+ EDTA disc were placed at a distance of 10 
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mm edge to edge. The plates were incubated overnight at 35°C for 
24 hours. 
 The organisms were considered to be MBL producers if the 
increase in the inhibition zone of the IPM+EDTA disk was ≥ 5 
mm than the plain IPM disc. 
Screening test for AmpC β -lactamases  
 All the Gram negative isolates were screened for AmpC β 
lactamase production by the disc antagonism test using Cefoxitin 
(30μg) disc by disc diffusion method. The isolates which showed 
a reduced susceptibility to Cefoxitin ≤ 18 mm were tested for 
confirmation by the AmpC Disc test.  
Detection of AmpC β -lactamases by Disc test 
 The isolates resistant to cefoxitin were subjected to AmpC Disc 
test.[95]  
 A lawn culture of E. coli ATCC 25922 was prepared on Muller 
Hinton agar (MHA) plate. Sterile disks (6 mm) were moistened 
with sterile 0.85% saline (20μl) and inoculated with several 
colonies of the test organism.  
 The inoculated disc was then placed beside a Cefoxitin disc 
(almost touching) on the inoculated plate. The plates were 
incubated overnight at 35°C.  
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 A positive test appeared as a flattening or indentation of the 
Cefoxitin inhibition zone in the vicinity of the test disc.  
 A negative test had an undistorted zone around the Cefoxitin disc.  
Screening test for Detection of Methicillin Resistance in 
Staphylococcus species 
      The Staphylococcal isolates were tested for methicillin 
resistance using Cefoxitin (30µg) by disc diffusion method in MHA 
plate. Cefoxitin is used as a surrogate marker for mec-A mediated 
oxacillin resistance. Zone size of ≤21mm for Staphylococcus aureus and 
Staphylococcus lugdunensis, ≤ 24mm for CoNS species around 
Cefoxitin disc were considered as methicillin resistant as per CLSI 
guidelines. Staphylococcus aureus ATCC 25923 was used as quality 
control strain.
 [90] 
Phenotypic detection of Biofilm production by isolates from 
colonized Double -J ureteral stents detected by Microtitre plate 
method 
 The procedure was done as described by Stepanovic et al.[63]  
 Isolates from recently subcultured 5% sheep BAP plates were 
inoculated in trypticase soy broth with 1% glucose media and 
incubated for 18 hours at 37oC and then diluted 1in100 with 
trypticase soy broth.  
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 Individual wells of sterile polystyrene, 96 well-flat bottom 
microtitre plates were filled with 200 µl of the diluted cultures 
and uninoculated trypticase soy broth broth served as control to 
check sterility and non-specific binding of media. The test was 
conducted in triplicate for concurrence.  
 The microtitre plates were incubated for 18 - 24 hours at 37°C. 
After incubation, the content from each well was gently removed 
by tapping the plates. The wells were washed four times with 200 
µl of phosphate buffer saline (PBS) pH 7.2 to remove free-
floating „planktonic‟ bacteria.  
 Biofilms formed by adherent „sessile‟ organisms in plate were 
fixed with 200 µl sodium acetate (2%) . 200 μl of 0.1%(W/V) 
aqueous crystal violet solution was added to each well and 
allowed to stand for 15 minutes. 
 Excess stain was rinsed off by thorough washing with deionized 
water and plates were kept for drying. 200 μl of 95% ethanol was 
added to solubilize bound crystal violet. 
 Adherent cells usually form biofilm and the microtitre wells were 
uniformly stained with crystal violet. Optical density (OD) of 
stained adherent bacteria was determined with a ELISA auto 
reader at wavelength of 570 nm.  
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 Quality Control Strains:  Pseudomonas aeruginosa ATCC 27853 a 
strong biofilm producer was used as positive control. Escherichia 
coli ATCC 25922 a non biofilm producer was used as negative 
control.[96] 
Interpretation 
 The average OD values were calculated for all tested strains and 
negative controls, since all tests were performed in triplicate.  
 The cut-off value (ODc) is defined as three standard deviations 
(SD) above the mean OD of the negative control:  
  ODc=average OD of negative control + (3× SD of negative 
control).  
 Isolates were categorized as  
Non biofilm producer : OD ≤ ODc 
Weak biofilm producer  : ODc    ≤ OD ≤ 2ODc 
Moderate biofilm producer : 2ODc ≤ OD ≤ 4 ODc 
Strong biofilm producer : 4ODc < OD        
STATISTICAL ANALYSIS 
     Results were analyzed statistically using statistical package of social 
sciences (SPSS) version 20.0. Pearson‟s chi square test and fisher‟s 
exact test were used and a p value of < 0.05 was considered significant.  
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RESULTS 
This cross sectional study was carried out in the Institute of 
Microbiology, Madras Medical College, in association with the 
Department of Urology, Rajiv Gandhi Government General Hospital, 
Chennai. A total of 100 patients who were treated with Double-J ureteral 
stents for relief of ureteral obstruction and who satisfied the inclusion 
criteria were included in this study for from November 2014 to August 
2015. 
Table-1: ANALYSIS OF AGE AND GENDER DISTRIBUTION OF 
PATIENTS WITH DOUBLE-J URETERAL STENT PLACEMENT 
(n=100) 
Age group 
Number of 
patients 
Gender 
Percentage 
Male Female 
20-30 28 16 12 28% 
31-40 7 14 13 27% 
41-50 25 13 12 25% 
51-60 13 6 7 13% 
61-70 6 2 4 6% 
71-80 1 1 0 1% 
Total 100 52 48 100% 
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FIGURE 1: DISTRIBUTION OF PATIENTS WITH DOUBLE-J 
URETERAL STENT PLACEMENT ACCORDING TO AGE AND 
GENDER 
 
The age (in years) ranged from 20 to 75 years. The mean ± SD of 
age (in years) of patients treated with indwelling Double-J ureteral 
stents was 40.45± 12.534.Majority of the patients were in the age group 
of 31-50 years. Out of 100 patients 52 were males and 48 were females.  
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TABLE 2: ANALYSIS OF PATIENTS BASED ON DOUBLE-J 
URETERAL STENT AND URINE CULTURE RESULTS (N=100) 
Double-J ureteral stent colonization 
(n=100) 
Urine Culture (n=100) 
Total 
Negative Positive 
Present 31 36 67 
Absent 33 0 33 
Total 64 36 100 
Figure 2: DISTRIBUTION OF PATIENTS BASED ON DOUBLE-J 
URETERAL STENT AND URINE CULTURE RESULTS 
 
Out of 100 patients with Double-J ureteral stent placement, 67 
patients had colonization of Double-J ureteral stent surface while only 
36 patients had positive urine culture. In 33 patients both Double-J 
ureteral stent and urine culture were negative. 
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TABLE 3: ANALYSIS OF AGE WISE DISTRIBUTION OF 
PATIENTS WITH COLONIZED DOUBLE-J URETERAL STENT 
AND POSITIVE URINE CULTURE (n=100) 
Age 
group 
(years) 
Total 
number of 
patients 
Number of patients 
with colonized 
Double-J ureteral 
stent 
Number of 
patients with 
positive urine 
culture 
20-30 28 20 (71.4%) 10 (35.7%) 
31-40 27 15 (55.6%) 8 (29.6%) 
41-50 25 19 (76%) 10 (52.6%) 
51-60 13 9 (69.2%) 7 (53.8%) 
61-70 6 3 (50%) 0 
71-80 1 1 (100%) 1(100%) 
Total 100 67 36 
The colonization of Double-J ureteral stent is higher in the 41-50 
years age group followed by those between 20-30 years of age. Patients 
between 51-60 years had higher percentage of positive urine culture.  
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TABLE 4: GENDER WISE DISTRIBUTION OF COLONIZED AND 
NON-COLONIZED STENTS (n=100) 
Double-J 
ureteral 
stent 
Gender Pearson 
Chi-
Square Male Female Total 
N % N % N %  
P-Value 
0.946 
Colonized 35 67.3 32 66.7 67 67 
Non-
colonized 
17 32.7 16 33.3 33 33 
Total 52 100 48 100 100 100 
FIGURE-3: GENDER WISE DISTRIBUTION OF COLONIZED 
AND NON-COLONIZED STENTS 
 
There was statistically no significant relationship between 
Double-J ureteral stent colonization and gender (p > 0.05).  
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TABLE 5: INDICATIONS FOR DOUBLE-J URETERAL STENT 
PLACEMENT (n=100) 
Indications 
Number of 
Cases (n) 
Percentage (%) 
Ureteroscopic (URS) stone 
Extraction/Lithotripsy 
62 62 
After Percutaneous 
nephrolithotomy (PCNL) 
17 17 
Prior to Extracorporeal shockwave 
Lithotripsy (ESWL) 
14 14 
Hydronephrosis 2 2 
Open Urolithiasis surgery 5  
Total 100 100 
In majority of the patients (62%) Double-J stents were placed 
following Ureteroscopic stone extraction/ Lithotripsy, followed by 
ureteral stenting in patients who have undergone PCNL (17%) and prior 
to ESWL (14%). 
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TABLE 6: CORRELATION BETWEEN DURATION OF STENT 
PLACEMENT AND COLONIZATION OF DOUBLE-J URETERAL 
STENTS AND URINE CULTURE 
Cuture Results 
Duration Of Stent Placement 
< 4 
WKS 
4 - 6 
WKS 
>6 WKS Total 
N % N % N % N % 
Negative urine culture and 
non colonized stent 
31 43.1 2 11.1 0 0 33 33 
Negative urine culture and 
colonized stent 
29 40.3 2 11.1 0 0 31 31 
Positive urine and colonized 
stent 
12 16.7 14 77.8 10 100.0 36 36 
Total 72 100 18 100 10 100 100 100 
 
Chi-Square Test Value P-Value 
Fisher's Exact Test 40.349 <0.001 
The duration of stent placement had statistically significant 
influence on the rate of bacteriuria and Double-J ureteral stent 
colonization (p <0.001). When the duration of stent placement is > 6 
weeks urine culture and Double-J ureteral stent colonization is 100% 
positive. 
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TABLE-7: MICROBIOLOGICAL PROFILE IN PATIENTS WITH 
POSITIVE DOUBLE-J URETERAL STENT CULTURE (n=100) 
Type of isolate Organism 
Total number of 
isolates (n) 
Percentage 
Gram Negative 
Bacilli 
Escherichia coli 22 32.4% 
Klebsiella oxytoca 11 16.2% 
Klebsiella 
pneumoniae 
2 2.9% 
Pseudomonas 
aeruginosa 
18 26.5% 
Acinetobacter 
baumannii 
1 1.5% 
Gram Positive 
Cocci 
Staphylococcus 
aureus 
4 5.9% 
Staphylococcus 
epidermidis 
2 2.9% 
Enterococcus 
faecalis 
4 5.9% 
Yeast Candida tropicalis 3 4.4% 
Candida krusei 1 1.5% 
Total 68 100.0% 
The most commonly isolated pathogen in Double-J ureteral stent 
culture was Escherichia coli (32.4%).  Pure growth was isolated from 
the Double-J ureteral stent surface in 66 patients and one patient had 
colonization with 2 microorganisms namely Klebsiella pneumoniae and 
Staphylococcus epidermidis.  
 1 
FIGURE-4: MICROBIOLOGICAL PROFILE IN PATIENTS WITH 
POSITIVE DOUBLE-J URETERAL STENT CULTURE (%)  
(TABLE-7) 
 
 
 
FIGURE-5: MICROBIOLOGICAL PROFILE IN PATIENTS WITH 
POSITIVE URINE CULTURE (%)  (TABLE 8) 
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TABLE 8: MICROBIOLOGICAL PROFILE OF URINE CULTURE 
IN PATIENTS WITH DOUBLE-J URETERAL STENT 
PLACEMENT 
Type of isolate Organism 
Total number of 
isolates (n) 
Percentage 
Gram Negative 
Bacilli 
Escherichia coli 13 34.2% 
Klebsiella oxytoca 5 13.2% 
Klebsiella 
pneumoniae 
1 2.6% 
Pseudomonas 
aeruginosa 
11 28.9% 
Gram Positive 
Cocci 
Staphylococcus 
aureus 
1 
2.6% 
Staphylococcus 
epidermidis 
1 
2.6% 
Enterococcus 
faecalis 
3 7.9% 
Yeast Candida tropicalis 3 7.9% 
Total 38 100% 
Microbiological profile of urine culture showed Escherichia coli 
to be the commonest pathogen (34.2%) followed by Pseudomonas 
aeruginosa (28.9%). Out of the 36 patients who showed growth in urine 
culture, 34 patients had growth of single microorganism. Mixed growth 
in the urine sample of two patients were Pseudomonas aeruginosa + 
Staphylococcus epidermidis and Pseudomonas aeruginosa + 
Enterococcus faecalis. 
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TABLE-9: ANTIBIOTIC SENSITIVITY PATTERN OF GRAM NEGATIVE BACILLI 
S. 
NO 
ANTIBIOTIC 
Escherichia 
coli (n=22) 
Klebsiella 
oxytoca 
(n=11) 
Klebsiella 
pneumoniae 
(n=2) 
Pseudomonas 
aeruginosa 
(n=18) 
Acinetobacter 
baumannii 
(n=1) 
Total 
Percentage 
Sensitivity 
S % S % S % S % S % % 
1 Ampicillin (10µg) 1 4.5 - - - - - - - - 4.5 
2 Gentamicin (10µg) 6 27.3 3 27.3 0 0 10 55.6 1 100 37 
3 Amikacin  (30µg) 11 50 3 27.3 2 100 10 55.6 1 100 50 
4 Ciprofloxacin (5µg) 4 18.2 2 18.2 1 50 5 27.8 1 100 24.1 
5 Trimethoprim-
sulfamethoxazole 
(1.25/23.75µg) 
6 27.3 5 45.5 1 50 - - 1 100 36.1 
6 Cefotaxime (30µg) 3 13.6 2 18.2 0 0 - - 1 100 16.7 
7 Ceftazidime (30µg) 6 27.3 4 36.4 0 0 7 38.9 1 100 33.3 
8 Imipenem (10µg) 18 81.8 9 81.8 2 100 16 88.9 1 100 84.9 
9 Piperacillin-
Tazobactum 
(100/10µg) 
12 54.5 6 54.5 2 100 10 55.6 1 100 56.6 
10 Tetracycline (30µg) 8 36.4 6 54.5 2 100 - - 1 100 47.2 
11 Ofloxacin (5µg) 7 31.8 2 18.2 1 50 4 22.2 - - 25 
12 Norfloxacin  (10µg) 9 40.9 5 45.5 1 50 10 55.6 - - 46.2 
13 Nitrofurantoin (300µg) 14 63.6 6 54.5 0 0 - - - - 57.1 
S- Sensitive 
All the identical isolates identified from Double-J ureteral stent culture and urine culture had same susceptibility pattern.  
All the Gram negative bacilli were highly susceptibile to Imipenem (84.9%) and Nitrofurantoin (57.1%).  
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                                TABLE-10: ANTIBIOTIC SENSITIVITY PATTERN OF GRAM POSITIVE COCCI 
S.NO ANTIBIOTIC 
Staphylococcus 
aureus (n=4) 
Staphylococcus 
epidermidis (n=2) 
Enterococcus 
faecalis (n=4) Percentage 
Sensitivity 
S % S % S % 
1 Ampicillin (10µg) - - - - 0 0 0% 
2 Pencillin (10 Units) 0 0 0 0 0 0 0% 
3 Trimethoprim-sulfamethoxazole  
(1.25/23.75µg) 
0 0 1 50 - - 16.7% 
4 Linezolid (30µg) 4 100 2 100 4 100 100% 
5 Vancomycin (30µg) - - - - 4 100 100% 
6 Tetracycline (30µg) 4 100 1 50 3 75 80% 
7 High-level Gentamicin (120µg)     4 100 100% 
8 Ciprofloxacin (5µg) 0 0 1 50 1 25 20% 
9 Norfloxacin  (10µg) 2 50 1 50 0 0 30% 
10 Nitrofurantoin (300µg) 4 100 1 50 2 50 70% 
S-sensitive 
The Gram positive organisms were highly susceptible to Linezolid (100%), Tetracycline (80%) followed by 
Nitrofurantoin (70%) and least susceptible to Trimethoprim-sulfamethoxazole (16.7%). All the isolates tested were 
resistant to Ampicillin and Penicillin.  
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FIGURE-6: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF 
ESCHERICHIA COLI ISOLATES FROM PATIENTS WITH 
DOUBLE-J URETERAL STENT PLACEMENT (TABLE 9) 
 
 
FIGURE-7: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF 
KLEBSIELLA OXYTOCA ISOLATES FROM PATIENTS WITH 
DOUBLE-J URETERAL STENT PLACEMENT (TABLE 9) 
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FIGURE 8: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF 
KLEBSIELLA PNEUMONIAE ISOLATES FROM PATIENTS WITH 
DOUBLE-J URETERAL STENT PLACEMENT (TABLE 9) 
 
 
FIGURE 9: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF 
PSEUDOMONAS AERUGINOSA ISOLATES FROM PATIENTS 
WITH DOUBLE-J URETERAL STENT PLACEMENT (TABLE 9) 
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FIGURE 10: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
ENTEROCOCCUS FAECALIS ISOLATES FROM PATIENTS 
WITH DOUBLE-J URETERAL STENT PLACEMENT (TABLE 10)  
 
 
 
FIGURE-11: ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF 
STAPHYLOCOCCUS AUREUS ISOLATES FROM PATIENTS 
WITH DOUBLE-J URETERAL STENT PLACEMENT (TABLE 10) 
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TABLE 11: ANALYSIS OF DISTRIBUTION OF RESISTANCE 
PATTERN IN GRAM NEGATIVE BACILLI (N=53) 
GRAM 
NEGATIVE 
BACILLI (n=53) 
Extended-
Spectrum Beta 
Lactamases 
(ESBL) 
Metallo-Beta-
lactamases 
(MBL) 
AmpC Beta-
lactamases 
 
 
N % N % N % 
Escherichia coli 
(n=22) 
16 72.7 4 18.2 1 4.5 
Klebsiella oxytoca 
(n=11) 
6 54.5 1 9.1 2 18.2 
Klebsiella 
pneumoniae (n=2) 
1 50% 0 0 0 0 
Pseudomonas 
aeruginosa (n=18) 
- - 2 11.1 3 16.7 
Total 23 65.7% 7 13.2% 6 11.3% 
 Out of 35 isolates tested for ESBL production 23 isolates (65.7%) 
were found to be ESBL producers. Among the 53 isolates tested, 
7(13.2%) were MBL producers and 6 (11.3%) were AmpC β-lactamases 
producers.  
 5 
 
 
FIGURE-12: DISTRIBUTION OF RESISTANCE PATTERN IN 
GRAM NEGATIVE BACILLI ISOLATED FROM PATIENTS 
WITH DOUBLE-J URETERAL STENTS 
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TABLE-12:  DETECTION OF RESISTANCE PATTERN OF 
STAPHYLOCOCCUS SPP. BY CEFOXITIN DISC DIFFUSION 
TEST 
Organism 
Number of 
isolates ( n) 
Methicillin 
sensitive 
Methicillin 
resistant 
N % N % 
Staphylococcus 
aureus  
4 2 50 2 50 
Staphylococcus 
epidermidis  
2 1 50 1 50 
Out of the 4 Staphylococcus aureus isolates (50%) were 
methicillin resistant and one Staphylococcus epidermidis isolate (50%) 
was methicillin resistant. 
TABLE 13: INTERPRETATION OF MINIMUM 
INHIBITORY CONCENTRATION (MIC) OF VANCOMYCIN FOR 
METHICILLIN RESISTANT STAPHYLOCOCCUS SPP. BY 
BROTH MACRODILUTION METHOD 
Organism 
Number of 
Methicillin 
resistant isolates 
MIC 
values 
µg/ml 
Interpretation 
Staphylococcus 
aureus (n=4) 
2 ≤ 2 Sensitive 
Staphylococcus 
epidermidis (n=2) 
1 ≤ 4 Sensitive 
All the Methicillin resistant Staphylococcal isolates were 100% 
sensitive to Vancomycin. 
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TABLE-14: INTERPRETATION OF MINIMUM INHIBITORY 
CONCENTRATION (MIC) OF MEROPENEM FOR IMIPENEM 
RESISTANT GRAM NEGATIVE BACILLI BY BROTH 
MACRODILUTION METHOD 
Gram 
Negative 
Bacilli 
Imipenem 
resistant 
isolates 
MIC values µg/ml 
Interpretation 
≤ 2 4 8 16 32 64 
Escherichia 
coli (n=22) 
3 - - - 1 2 - Resistant 
Klebsiella 
oxytoca 
(n=11) 
2 - - - 1 1 - Resistant 
Pseudomonas 
aeruginosa  
(n=18) 
2 - - - 1 1 - Resistant 
All the 7 Imipenem resistant Gram negative bacilli (100%) were 
found to be resistant to Meropenem. 
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TABLE-15: DISTRIBUTION OF CANDIDA ISOLATES IN 
DOUBLE-J URETERAL STENT AND URINE CULTURE 
Candida species 
(n=4) 
Double-J ureteral stent 
culture 
Urine 
culture 
Candida tropicalis (n=3) 3 3 
Candida krusei (n=1) 1 0 
 
FIGURE-13: DISTRIBUTION OF CANDIDA ISOLATES IN 
PATIENTS WITH DOUBLE-J URETERAL STENT 
 
All the three Candida tropicalis isolated from patients with 
Double-J ureteral stent placement were present in both Double-J ureteral 
stent surface and urine culture. Candida krusei was present in Double-J 
ureteral stent surface only. 
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TABLE-16: ANTIFUNGAL SENSITIVITY PATTERN OF 
CANDIDA SPP. BY DISC DIFFUSION METHOD 
Candida 
species 
Number of 
isolates 
Fluconazole 
(25µg) 
Voriconazole 
(1µg) 
S % S % 
Candida 
tropicalis 
3 1 33.3% 1 33.3% 
Candida krusei 1 0 0 0 0 
Only one Candida tropicalis isolate was sensitive to both 
Fluconazole and Voriconazole (33.3%), other 2 isolates of Candida 
tropicalis and one isolate of Candida krusei were resistant to both 
antifungal agents. 
TABLE-17:  INTERPRETATION OF MINIMUM INHIBITORY 
CONCENTRATION (MIC) OF AMPHOTERICIN-B FOR 
CANDIDA SPP. BY BROTH MICRODILUTION METHOD 
Candida 
species 
Number of 
Isolates 
MIC Values 
Interpretation Sensitive 
≤ 1 
µg/ml 
Resistant 
>1 µg/ml 
Candida 
tropicalis (n=3) 
3 3 0 Sensitive 
Candida krusei 
(n=1) 
1 1 0 Sensitive 
All the four Candida isolates were found to be 100% sensitive for 
Amphotericin B. 
 78 
TABLE-18: PHENOTYPIC DETECTION OF BIOFILM 
PRODUCTION BY MICROTITRE PLATE METHOD 
Organism 
Strong 
Biofilm 
Producers 
Moderate 
Biofilm 
Producers 
Weak 
Biofilm 
Producers 
Non-
biofilm 
producers 
Escherichia coli 
(n=22) 
9 (41%) 5(22.7%) 4(18.2%) 4(18.2%) 
Klebsiella 
oxytoca (n=11) 
4 (36.4%) 4(36.4%) 1(9.1%) 2(18.2%) 
Klebsiella 
pneumoniae 
(n=2)  
0 1 (50%) 1 (50%) 0 
Pseudomonas 
aeruginosa 
(n=18) 
6(33.3) 4(26.7%) 5(27.8%) 3(16.7%) 
Acinetobacter 
baumannii (n=1) 
0 1(100%) 0 0 
Staphylococcus 
aureus (n=4) 
2 (50%) 2 (50%) 0 0 
Staphylococcus 
epidermidis 
(n=2) 
0 2 (100%) 0 0 
Enterococcus 
faecalis (n=4) 
2 (50%) 1(25%) 1(25%) 0 
Candida 
tropicalis (n=3) 
3 (100%) 0 0 0 
Candida krusei 
(n=1) 
1 (100%) 0 0 0 
TOTAL 27 
(39.7%) 
20(29.4%) 12(17.6%) 9(13.2%) 
 79 
Figure-14: Phenotypic Detection of Biofilm Production by Microtitre 
Plate Method 
 
Out of the 68 isolates 59 isolates (86.8%) were biofilm producers 
and only 9 (13.2%) were non-biofilm producers. All the four Candida 
isolates (100%) were strong biofilm producers.  
COLOUR PLATE 1:  VIDEO ENDOSCOPIC UNIT 
 
 
COLOUR PLATE 2:  URETEROSCOPE 
 
 
COLOUR PLATE 3: ENDOSCOPIC VIEW OF URETERAL 
CALCULUS 
 
 
COLOUR PLATE 4:  DOUBLE-J URETERAL STENT 
 
COLOUR PLATE 5: DIRECT GRAM STAIN OF URINE 
SAMPLE SHOWING PLENTY OF GRAM NEGATIVE BACILLI 
 
 
COLOUR PLATE 6:  ESCHERICHIA COLI COLONIES FROM 
URINE CULTURE ON MACCONKEY AGAR PLATE 
 
 
COLOUR PLATE 7: ESCHERICHIA COLI COLONIES FROM 
URINE CULTURE ON 5% SHEEP BLOOD AGAR PLATE 
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FOR ESBL PRODUCTION 
 
 
    COLOUR PLATE 10: DETECTION OF METALLO-β 
LACTAMASE PRODUCTION BY DOUBLE DISC SYNERGY 
TEST                                        
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COLOUR PLATE 15: SUGAR ASSIMILATION PATTERN OF CANDIDA 
TROPICALIS 
                         
                                   
                           
Sugars assimilated are Dextrose (De), Sucrose (Su), Maltose (Ma),Xylose(Xy), 
Cellobiose(Ce), Trehalose (Te). 
Sugars not assimilated are Lactose(La), Raffinose(Rf), Inositol(Is), Dulcitol(Du) . 
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COLOUR PLATE 17: ANTIFUNGAL SUSCEPTIBILITY PATTERN BY 
DISC DIFFUSION METHOD 
 
 
COLOUR PLATE 18: DETERMINATION OF AMPHOTERICIN B 
MIC BY BROTH MICRODILUTION METHOD 
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DISCUSSION 
One of the most common indications for Double-J ureteral stent 
placement is for relief of ureteral obstruction due to ureteral stones. The 
widespread use of Double-J ureteral stents has lead to an increase in 
complications, including infection, encrustation, stone formation, and 
fragmentation.
 [38]
 Ureteral stents are synthetic biomaterials and like any 
other catheter that dwells in the urinary tract, it also provides a suitable 
surface for bacterial colonization and development of biofilm. Microbial 
ureteral stent colonization (MUSC) plays an essential role in the 
pathogenesis of stent-associated infections. 
In this study, out of 100 patients treated with Double-J ureteral 
stents for ureteral obstruction, 52 were males and 48 were females. 
Majority of the patients (52%) were in the age group of 31to 50 years, 
out of which 27 were males and 25 were females (Table 1).                       
In the study group of 100 patients treated with Double-J ureteral 
stents for ureteral obstruction, culture of the Double-J ureteral stent 
surface showed MUSC in 67% of the patients, while only 36% of the 
patients with colonization had positive urine culture. Both urine and 
Double-J stent culture showed no growth in 33% of the patients. The 
rate of Double-J ureteral stent colonization (67%) was much higher than 
the rate of urinary tract infection (36%) in our study (Table 2).                             
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In this study it was analyzed and found that urine culture was positive in 
only those patients in whom Double-J ureteral stent colonization was 
present.  
The results were similar to Farsi and colleagues, 1995 who noted 
in their prospective study that urine cultures were positive in 29.9%, 
while stent colonization was found in 67.9%.
[97] 
There are different rates 
of bacterial stent colonization and bacteriuria reported in the literature. 
The observations made by Kehinde et al in 2002, point to more than 2.5-
fold higher risk of stent colonization than urinary tract infection. 
[98]
 
Klis et al in their 2014 study noted that the rate of stent colonization 
was 100% and was 8-fold higher than the incidence of bacteriuria 
(13.3%).
 [99]
 Al-Ghazo et al 2010 considered that the lower rate of stent 
colonization (24.2%) and bacteriuria (22.5%) noted in their study might 
be related to the use of ciprofloxacin, a broad spectrum antibacterial 
drug used for 5 days as prophylactic therapy before Double -J ureteral 
stent insertion.
[100] 
The differences in the rate of Double-J stent colonization and 
urine infection may be due to varying sample size, age and gender 
distribution of the patients, patients with concomitant illness, type of 
ureteral stent inserted, indication for stent insertion as a elective or 
emergency procedure, use of prophylactic antibiotic therapy and 
different methods used for colonization estimation such as culture of the 
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stent or by molecular DNA analysis.. Studies by Bonkat et al 2011 and 
Klis et al 2014 have shown that there is a great inconsistency between 
microbial ureteral stent colonization and urine infection, indicating a 
low predictive value of urine culture for estimating ureteral stent 
colonization.
 [59, 99] 
     Present study shows that there was no relationship between age of 
the patient Double-J ureteral stent colonization and positive urine 
culture (Table 3).  Yeniyol et al 2002, Akay and co-workers in 2007, 
Ozgur et al 2013 and Al-Ghazo et al 2010 also reported no significant 
relationship between age of the patient with infection of urinary tract 
and stent colonization in patients with Double-J ureteral stents.
 [101-
103,100]
  
In this study, gender of the patients had statisticially no 
significant effect on bacteriuria and Double-J ureteral stent colonization 
(Table 4). Observations made by Klis et al 2014 also showed that gender 
of the study group was not related to urine culture and colonization of 
Double-J ureteral stent surface.
[99]
 The results of our study are also 
comparable with the studies done in Turkey by Yeniyol et al 2002 and 
Akay et al 2007.
[101,102]
  Farsi and his collegues 1995 and Bonkat et al 
2011 in their studies reported female gender as a risk factor for stent 
colonization.
[97, 59]
 The shorter urethra and close proximity of urethral 
 83 
opening to the vagina and anus in females makes them more susceptibile 
to UTI. 
The commonest indication for stenting the urinary tract in this 
study was following ureteroscopic (URS) stone extraction /Lithotripsy 
(62%), followed by stenting after PCNL (17%) and prior to ESWL 
(14%) (TABLE 5). Al-Ghazo et al 2010 also reported that the major 
indication for Double-J stent insertion in their study was for stone 
disease in which 45% of the patients were treated with Double-J stent 
following URS stone extraction / Lithotripsy, 25% of cases prior to 
ESWL and 15% of cases after PCNL.
[100]
 Similarly Ozgur et al 2013 in 
their study on 130 patients found that 91 patients (70%) were treated 
with Double-J ureteral stents following stone fragmentation and to 
prevent ureteral edema.
[103] 
This study showed that longer the duration of stenting, the higher 
the rate of colonization. The rate of Double-J ureteral stent colonization 
was 56.9%, 88.8% and 100% when the duration of ureteral stent 
placement was less than 4 weeks, 4-6 weeks, and more than 6 weeks 
respectively.  Urine culture was found to be positive in 16.6%, 77.8% 
and 100% of the patients when the retention of Double-J ureteral stent 
was less than 4 weeks, 4-6 weeks, and more than 6 weeks respectively. 
In this study statistical analysis revealed significant correlation between 
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Double-J stent colonization, urine culture and duration of stent 
placement (Table 6). 
Similar results were seen in the study by Lojanapiwat from 
Thailand 2006 who reported positive Double-J ureteral stent 
colonization in 33%, 50%, and 54% of study population, when the 
insertion period was less than 4 weeks, 4-6 weeks, and more than 6 
weeks respectively.
[104]
 Urine culture was found to be positive in 75%, 
61% and 82% of the patients when the indwelling time was less than 4 
weeks, 4-6 weeks, and more than 6 weeks respectively.
[104]
 Rahman et al 
2010 from Bangladesh also reported that colonization rate was 71.4% in 
stents removed after 6 weeks compared to 33.3% in 4-6 weeks and 
23.5% before 4 weeks.
[105]
 Ozgur et al 2013 also observed that rate of 
colonization was 2.2%, 2.9% and 25% when the indwelling period of 
Double-J ureteral stent was less than 4 weeks, 4-6 weeks, and more than 
6 weeks respectively.
[103]
 
Paick et al 2003 reported in his trial that bacterial colonization 
begins 2 weeks after stenting.
 [106]
 The infection and colonization 
induction by internal ureteral stents are due to the introduction of the 
bacteria during stenting, entry of bacteria through the urethral meatus 
and ability of the bacteria to rise through a column of fluid.
 [107]
 Coskun 
et al 2011 stressed that early removal of the ureteral stent, 2 weeks after 
renal transplantation, decreased the rate of urinary tract infections.
[108]
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Out of the 68 isolates identified in our study from the colonized 
Double-J ureteral stent surface, the predominant pathogen isolated was 
Escherichia coli (32.4%), followed by Pseudomonas aeruginosa 
(26.5%) and Klebsiella oxytoca (16.2%). Only two isolates of Klebsiella 
pneumoniae and one isolate of Acinetobacter baumannii were isolated 
from Double-J ureteral stent. Among the Gram positive cocci 5.9% each 
of Staphylococcus aureus and Enterococcus faecalis were isolated. Out 
of the 5.9% of Candida spp. isolated, three were Candida tropicalis and 
one was Candida krusei (Table 7). In this study all except one stent 
were colonized by a single microorganism. Only one stent was colonized 
by two bacterial species namely Klebsiella pneumoniae and 
Staphylococcus epidermidis. 
The results of our study are comparable with the study done in 
Thailand by Lojanapiwat 2006 who also observed Escherichia coli as 
the most common pathogen (34.6%) followed by Pseudomonas 
aeruginosa (17.3%).
[104] 
Al-Ghazo et al 2010 from Jordan also isolated 
Escherichia coli (51.7%) as the predominant pathogen.
[100]
 The study 
from Nepal by Joshi et al 2011 also noted Escherichia coli as the 
commonest pathogen (14.89%) followed by Klebsiella and 
Acinetobacter spp. (4.25%).
[109]
 Escherichia coli is the predominant 
pathogen in most of the studies because it possesses several virulence 
factors like fimbrial protein, fim H which binds to Tamm-Horsfall 
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protein (THP). THP has been found to bind to ureteral stent surface and 
may act as a promoter of MUSC.
 [110] 
In contrast Bonkat et al 2011 from Switzerland found Coagulase 
negative staphylococcus (CoNS) (18.3%) and Enterococcus spp. 
(17.9%) as the predominant pathogens by sonicate fluid culture.
 [59]
 
Enterococcus spp. was reported as the predominant isolate by Reidl et al 
1999 (51%) and Paick et al 2003 (24%), while Pseudomonas aeruginosa 
(23%) was the most common pathogen isolated from the Double-J 
ureteral stent by Farsi and colleagues, 1995.
 [111, 106, 97] 
CoNS which frequently colonize the skin and mucus membrane 
were previously regarded as non pathogens but now they are recognized 
as the most frequent cause of biofilm-associated infections, as any 
medical device that penetrates these surfaces during surgery is at high 
risk to become colonized by CoNS. The variation in the type of isolated  
microorganisms in these studies may be due to the variations in the 
spectrum of pathogens in different hospitals and countries, the study 
population and the diagnostic technique used for identification.  
In the present study, Escherichia coli (34.2%), was the most 
common pathogen isolated from urine culture, followed by 
Pseudomonas aeruginosa (26.5%). Among the Gram positive cocci 
Enterococcus faecalis (7.9%) was the most common isolate. Candida 
tropicalis (7.9%) was the only fungus isolated from the urine samples. 
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In all patients with significant bacteriuria, the same organism was also 
isolated from the Double-J ureteral stent in pure culture. In two patients 
mixed culture were isolated from urine samples in addition to the same 
organism isolated from Double-J stent which were identified as 
Staphylococcus epidermidis and Enterococcus faecalis (Table 8).  
The results were similar to the studies of Al-Ghazo et al 2010 and 
Yeniyol et al 2002 which also isolated Escherichia coli as the 
predominant pathogen 51.9% and 80% respectively in urine and 
observed same microorganisms in ureteral stent surface and urine 
culture.
 [100, 101]
 Joshi et al, 2011 also reported Escherichia coli as the 
predominant isolate (11.6%) from urine culture in patients with ureteral 
stents.
 [109] 
The antibiotic susceptibility pattern of the Gram negative bacilli 
in the present study, determined by the Kirby –Bauer disc diffusion 
method showed that the isolates were sensitive to Nitrofurantoin 
(57.1%), Amikacin (50%), and Tetracycline (47.2%), Norfloxacin 
(46.2%) and least susceptibility to Ofloxacin (25%) and Ciprofloxacin 
(24.1%). All the Gram negative bacilli were highly susceptible to 
Imipenem (84.9%) and Piperacillin-Tazobactum (56.6%). All the 
isolates from Double-J ureteral stent surface and positive urine culture 
had same susceptibility pattern. (Table 9) 
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Pseudomonas aeruginosa was more susceptible to Norfloxacin 
(55.6%), Amikacin and Gentamicin (55.6%) and Ceftazidime (38.9%) 
compared to E.coli and Klebsiella spp. Escherichia coli was least 
susceptible to Ampicillin (4.5%).As per CLSI guidelines, Ampicillin 
was tested only for Escherichia coli, as other Gram negative bacilli are 
intrinsically resistant to Ampicillin. A single isolate of Acinetobacter 
baumannii was sensitive to the panel of antibiotics tested.  
The Gram positive cocci were highly susceptibile to Linezolid 
(100%), followed by Tetracycline (80%), Nitrofurantoin (70%) and were 
least susceptible to Ciprofloxacin (20%) and Trimethoprim-
sulfamethoxazole (16.7%). None of the Gram positive cocci were 
sensitive to Penicillin. All the four Staphylococcus aureus isolates were 
highly susceptible to Nitrofurantoin and Tetracycline (100%). The four 
Enterococcus faecalis isolates were 100% sensitive to Vancomycin and 
High-level Gentamicin. (Table 10) 
The results are similar to study by Chatterjee et al 2014 who 
reported Vancomycin (63%) and Imipenem (81.6%) as the most 
sensitive drug in Gram positive and Gram Negative bacteria.
[112]
 
Manjunath et al 2011 from Bangalore also reported high reistance of 
E.coli isolated from urine to Ampicillin (<90%). Pseudomonas spp. was 
more resistant to Ofloxacin (81%), Ciprofloxacin (85%) and Imipenem 
(72%).
[113]
 Our results were also comparable with the study done in 
 89 
Rajasthan by Dalela et al 2012 which showed maximum sensitivity of 
Gram negative bacilli for Imipenem (95.1%), followed by 
Piperacillin/Tazobactum (71.8%), Amikacin (66.9%) and Nitrofurantoin 
(54.2%). Their study also documented 100% sensitivity of Gram 
positive cocci for Vancomycin and Linezolid.
 [114] 
Escherichia coli (72.7%) was the major ESBL producer in our 
study, followed by Klebsiella oxytoca (54.5%). AmpC β-lactamase 
production was more in Klebsiella oxytoca (18.2%) and Pseudomonas 
aeruginosa (16.7%). Metallo-Beta lactamase production was high in 
Escherichia coli (18.2%) and Pseudomonas aeruginosa (11.1%). 
(TABLE 11) 
The results of this study coincides with the study by Dalela et al 
2012 where they reported among the uropathogens maximum ESBL 
activity was in Escherichia coli (73.5%).
 [114]
 Chakraborty et al 2013 
analyzed drug resistant extra intestinal Escherichia coli isolates and 
stated that among the isolates from urology ward 15% were ESBL 
producers and13% were AmpC producers which were also highly 
resistant to fluoroquinolones and sulfonamides.
[115]
  
Cefoxitin is a surrogate marker to detect mec-A mediated 
Oxacillin resistance. Screening for Methicillin resistance with Cefoxitin 
disc showed, 50% of Staphylococcus aureus and 50% of Staphylococcus 
epidermidis isolates were resistant to Cefoxitin disc in this study. (Table 
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12).The results were consistent with that of Dalela et al 2012 which 
states that Methicillin resistance Staphylococcus aureus was seen in 
41.4% of urinary isolates.
 [114]
                
Susceptibility to Vancomycin was determined by Broth 
macrodilution method and all the three Methicillin resistant 
Staphylococcal isolates were 100% sensitive to Vancomycin. The break 
point concentrations of the Staphylococcus aureus isolates were 1µg/ml 
and 2µg/ml and that of Staphylococcus epidermidis was 4µg/ml (Table 
13). 
This finding is similar to Al-Hassanwai et al 2012 from Iraq 
which reported out of the 3 Staphylococcus aureus isolated from urine 
samples 2 were MRSA and all were 100% sensitive to Vancomycin.
[116] 
Susceptibility to Meropenem was determined by Broth 
macrodilution method and all the Imipenem resistant Gram negative 
bacilli showed 100% resistance to Meropenem. All the imipenem 
resistant isolates were also MBL producers. (Table 14) 
The results of this study agree with Boera et al 2014 which 
reported that 75.6% and 71.9% of MBL producing Escherichia coli and 
Klebsiella pneumoniae isolated in their study were all resistant to 
Imipenem and Meropenem.
[117]
 The study by Mobashshera et al 2015 
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from Mumbai reported that strains moderately resistant to carbapenems 
were also MBL producers.
[118] 
All the three (100%) Candida tropicalis isolates were isolated 
from both Double-J ureteral stent surface and urine culture, while 
Candida krusei was isolated only from Double-J ureteral stent culture. 
(Table 15) 
Antifungal susceptibility pattern of Candida spp. to Fluconazole 
and Voriconazole was determined by disc diffusion method showed that 
only one  isolate Candida tropicalis was sensitive (33%) to both the 
antifungal agents. Candida krusei is inherently resistant to Fluconazole, 
this study also showed similar result. (Table 16) 
Omar et al 2008 also reported that Candida spp. isolated from 
patients with obstructive uropathy were highly resistant to Fluconazole 
(55.7%) and Voriconazole.
[119]
 Kojic and Darouchie in 2004 have stated 
that indwelling medical devices can support Candida colonization and 
biofilm formation, and that the biofilm cells are relatively resistant to 
antifungal treatment.
[120] 
Susceptibility to Amphotericin B was determined by Broth 
microdilution method and all the four Candida isolates were found to be 
sensitive (100%). The range of antifungal concentration for 
Amphotericin B was 0.5 -1µg/ml. (Table 17) 
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The study by Omar et al 2008 from Egypt, also stated that 
Amphotericin B was an excellent antifungal drug with low MIC values 
for the susceptible strains of Candida tropicalis (0.25-1µg/ml) but with 
reduced activity to Candida krusei.
[119]
          
Phenotypic detection of biofilm production of the microorganisms 
isolated from the Double-J ureteral stent culture by the microtitre plate 
method showed that 39.7% isolates were strong biofilm producers, 
29.4% and 17.6% were moderate and weak biofilm producers 
respectively in this study. Among the Gram negative bacilli Escherichia 
coli was the predominant (41%) strong biofilm producer, followed by  
Pseudomonas aeruginosa (33.3%). 50% of the  Staphylococcus aureus  
isolates were  strong biofilm producers . All the four (100%) Candida 
isolates were strong biofilm producers. (Table 18)  
Our results were comparable with that of Chatterjee et al 2014 
who analyzed the biofilm formation on urological devices by microtitre 
plate method. They observed that all the Double-J ureteral stents (100%) 
analyzed by them showed monobacterial colonization and each of them 
was a biofilm producer in-vitro.
[112]
 Omar et al 2008 revealed that 
biofilm formation by Candida isolates was higher in obstructive 
uropathy patients compared to simple UTI and also observed high 
intensity of biofilm formation in Candida krusei isolates.
[119] 
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SUMMARY 
1) In this study, among 100 patients with ureteral obstruction due to 
urolithiasis, Double-J ureteral stents were placed in majority of 
patients (62%) following Ureteroscopic stone extraction 
/Lithotripsy. 
2) Majority of patients belonged to the age group of 20-30 years and 
80% were under 50 years in this study.  
3) In this study, males (52%) were commonly affected with 
urolithiasis and had undergone Double-J ureteral stents. 
4) Out of the one hundred patients who were treated with Double-J 
ureteral stents for ureteral obstruction, 67% of patients had 
Double-J ureteral stent colonization and only 36% had urinary 
tract infection. 
5) Age and gender of the patient had no statistically significant 
relationship with colonization of Double-J ureteral stent in this 
study.(p>0.946) 
6) The rate of colonization of the Double-J ureteral stent was 56.9%, 
88.8% and 100% when the retention of Double-J ureteral stent in 
urinary tract was less than 4 weeks, 4-6 weeks, and more than 6 
weeks respectively.  
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7) The duration of retention of Double-J ureteral stent in the urinary 
tract had a statistically significant influence on the rate of 
colonization of the Double-J ureteral stent and bacteriuria (p< 
0.001).  
8) Escherichia coli was the predominant pathogen (32.4%) isolated 
from Double-J stent culture as well as from the culture of urine 
samples (34.2%) from patients treated with Double-J ureteral 
stent. 
9) The Gram negative bacilli isolated were sensitive to 
Nitrofurantoin(57.1%) Amikacin (50%), Tetracycline (47.2%) and 
Norfloxacin (46.2%). Majority of the Gram negative bacilli were 
sensitive to Imipenem (84.9%) followed by Piperacillin-
tazobactum (56.6%). 
10) Out of the 10 Gram positive isolates from colonized Double-J 
ureteral stents, Staphylococcus aureus and Enterococcus faecalis 
were the common isolates. The Gram positive cocci were highly 
sensitive to Linezolid (100%), Tetracycline (80%) followed by 
Nitrofurantoin (70%) and least susceptible to Ciprofloxacin (20%) 
and Trimethoprim-sulfamethoxazole (16.7%).None of the Gram 
positive cocci isolated were sensitive to Penicil lin.  
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11) Among the Gram negative bacilli 65.7% of the isolates were 
ESBL producers, 13.2% were MBL producers and 11.3% were 
AmpC producers. Majority of Escherichia coli isolates (72.7%) 
were ESBL producers. 
12) Minimum inhibitory concentration of Meropenem determined by 
broth macrodilution method showed that all the Imipenem 
resistant Gram negative bacilli were also resistant to Meropenem.  
13) Two isolates of Staphylococcus aureus and one Staphylococcus 
epidermidis isolate were found to be Methicillin resistant. All the 
three isolates were sensitive to Vancomycin (100%) determined 
by broth macrodilution method.  
14) Antifungal susceptibility pattern by disc diffusion method showed 
that 33.3% of Candida tropicalis were sensitive to both 
Fluconazole and Voriconazole and one isolate of Candida krusei  
was resistant to both Fluconazole and Voriconazole.  
15) Antifungal susceptibility pattern by broth microdilution method 
showed all the fungal isolates (100%) were sensitive to 
Amphotericin B. 
16) Biofilm production by the microorganisms isolated from the 
Double-J stent surface was detected by microtitre plate method 
and 86.8% of the isolates were found to be biofilm producers.  
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17) Among the biofilm forming microorganisms 39.7% of the isolates 
were strong biofilm producers. 
18) Among the Gram negative bacilli Escherichia coli was the strong 
biofilm producer (41%). 
19) Among Gram positive cocci (50%) Staphylococcus aureus were 
strong biofilm producers and Staphylococcus epidermidis was 
identified as a moderate biofilm producer.  
20) Candida tropicalis and Candida krusei were strong biofilm 
producers. 
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CONCLUSION 
Double-J ureteral stent retention in the urinary tract is associated 
with an extremely high risk of bacterial colonization. A strong correlation 
has been identified between urine infection and Double-J stent 
colonization. As microbial ureteral stent colonization does not necessarily 
lead to bacteriuria, negative urine culture does not rule out biofilm 
formation, hence urine culture has a low predictive value for ureteral stent 
colonization.  Since undetected biofilms may still serve as a reservoir of 
pathogenic microorganisms, this assumes clinical significance. 
According to this study Double-J ureteral stent has to be ideally retained 
for less than four weeks, if it exceeds four weeks increased incidence of 
bacterial colonization of stent occurs and UTI is inevitable. In certain 
conditions where Double-J ureteral stent has to be retained for more than four 
weeks, it is better to start the patient on broad spectrum antibiotics to prevent 
further UTI.  Further prospective studies are needed to determine the optimal 
duration for Double-J stent placement after various urological procedures.                    
With increasing number of biomaterial devices used in urology, 
having an effective method for preventing biofilm formation is of 
utmost importance. The ideal ureteral stent biomaterial is yet to be 
identified and an area of promising development is the use of drug 
eluting stent to prevent infection and encrustation.  
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APPENDIX –I 
ABBREVIATIONS 
UTI  : Urinary tract infection. 
UVJ : Ureterovesical junction. 
UPJ : Ureteropelvic junction. 
UPEC : Uropathogenic Escherichia coli. 
MS adhesins : Mannose sensitive adhesins. 
MR adhesins : Mannose sensitive adhesins. 
ESWL : Extracorporeal shock wave Lithotripsy .  
URS : Ureterorenoscopy. 
Fr : French scale. 
PCNL : Percutaneous nephrolithotomy. 
CCDS : Colour-coded Doppler sonography. 
CLSM : Confocal scanning laser microscope. 
EPS : Extracellular polymeric substance. 
CFU : Colony Forming Unit. 
CCMU : Clean-Catch Midstream Urine. 
PMN : Polymorphonuclear neutrophils. 
MUSC : Microbial ureteral stent colonization. 
CRBSI : catheter-related blood stream infections. 
PFGE : Pulsed field gel electrophoresis  
PCR : Polymerase chain reaction. 
FISH  : Fluorescence in situ hybridization. 
SEM : Scanning electron microscopy. 
AFM : Atomic force microscopy. 
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PLGA : Poly-L-lactide-co-glycolide. 
PVP : Polyvinylpyrrolidone. 
PYR  : Pyrrolidonyl-beta-naphthylamide. 
SDA : Sabouraud dextrose agar. 
CoNS : Coagulase negative Staphylococcus  
CLSI : Clinical Laboratory Institute Standards. 
ATCC : American type culture collection. 
MIC : Minimum Inhibitory Concentration 
RPMI : Roswell Park Memorial Institute 
ESBL : Extended Spectrum Beta Lactamase. 
MBL : Metallo Beta Lactamase. 
APPENDIX II 
A. STAINS AND REAGENTS 
1. Gram Staining 
Smear is prepared on a clean glass slide, air dried and heat fixed. 
Smear is covered with 1% Methyl violet for 1 min. 
Washed with water and covered with Gram’s iodine for 1min. 
Washed with water and decolourized with acetone for 10 secs. 
Washed with water and counterstained with dilute carbol fuchsin for 30 secs. 
Washed with water, dried and observed under oil immersion. 
B. MEDIA USED 
1. MacConkey Agar  
           Peptone                                                              20gm 
           Sodium taurocholate                                            5 gm 
     Lactose, 10% aqueous solution                           2 gm 
     Neutral red solution, 2% in 50% ethanol         3.5 ml 
     Agar                                                                  20 gm 
     Distilled water                                               1000 ml 
     pH                                                                      7.4 
    All the ingredients except lactose were dissolved in distilled water by heating. The 
pH was adjusted to 7.4 and neutral red solution was added along with lactose. 
Sterilized by autoclaving at 121°C for 15 minutes and plates were poured. 
2. 5% sheep Blood Agar plate 
Peptone                     10gm 
Nacl                           5 gm 
Agar                          10gm 
Distilled water        1000 ml 
              This medium was prepared by adding 5 ml of sterile defibrinated sheep blood (5%) 
to 100 ml of Nutrient agar that had been melted and cooled to 50°C in a water bath. 
3. Cation adjusted Muller-Hinton Agar plate 
 Beef infusion                     300 ml 
Casein hydrolysate            17.5 gm 
Starch                                  1.5 gm 
Agar                                     10 gm 
Distilled water                  1000 ml 
    Starch was emulsified in small amount of cold water; beef infusion was poured, 
followed by addition of casein hydrolysate and agar. The constituents were 
dissolved by heating gently at 100°C with agitation. The pH was adjusted to 7.4 and 
sterilized by autoclaving at 121°C for 15 minutes and plates were poured. 
4. Phenolphthalein diphosphatase agar 
Sterilize 1% of aqueous solution of sodium phenolphthalein diphosphate by 
filtration and store at 4°C. Add 10 ml of this solution in 100ml of melted nutrient 
agar, cooled to 50°C and pour plates. The test organism is inoculated and plate is 
incubated at 37°C overnight. Invert the plates and pour few drops of ammonia 
solution SG 0.88 into the lid.The culture is positive when the colonies turn pink in 
a few minutes. The colour soon fades away. 
5. Sabouraud Dextrose Agar 
Dextrose                               40 gm 
Peptone                                10 gm 
Agar                                     15 gm 
Distilled water                  1000 ml 
pH                                        5.6 
The ingredients were dissolved in distilled water by boiling and autoclaved at 121°C for 
15 minutes. Then dispensed in tubes and allowed to cool in slanted position. 
6. Cornmeal Agar  
Cornmeal                              40 gm 
Tween 80                              10 ml 
Agar                                      20 gm 
Distilled water                   1000 ml 
Cornmeal was mixed with 500 ml of water and heated to 65°C for 1hour. Filtered 
through a gauze and pH was adjusted to 6.6 to 6.8, then agar was added dissolved in 
water, followed by tween 80. Plates were poured after autoclaving at 121°C for 15 
minutes. 
7. Preparation of Yeast nitrogen base for Sugar assimilation test 
 Yeast nitrogen base         6.7 gm 
Distilled water                 100 ml 
Sterilized by filtration and stored at 4°C. 
 Agar                                      20 gm 
           Distilled water                     980 ml 
Dispensed in 18 ml quantities, autoclaved at 121°C and stored at 4°C. 
8. Trypticase soy broth 
Tryptone 17 gm 
Phytone 3gm 
Nacl 5 gm 
Dipotassium phosphate 2.5 gms 
Glucose 2.5 gms 
Distilled water 1000 ml 
The ingredients are dissolved under gentle heat and sterilized by autoclaving at 121°C 
for 15 min at 15 psi. 
9. RPMI 1640 broth 
Dissolve 10.4 gm of RPMI 1640 powder and 34.5 gm MOPS buffer in 900 ml 
sterile distilled water. Adjust pH to 7.0 using 4M Naoh. Make up to 1 litre with 
sterile distilled water. Filter strilise using 0.22 µ filter. Check sterility and store at 
4°C. 
C. MEDIA REQUIRED FOR BIOCHEMICAL REACTIONS 
1. Oxidase test 
Filter paper soaked in oxidase reagent 1% Tetra methyl p-phenylene diamine 
dihyrochloride is placed in a petridish and the colony to be tested is smeared on it 
using a sterile glass rod.  Development of purple colour in 10 seconds is 
interpreted as a positive test. 
2. Catalase test 
A single colony to be tested is picked up with a sterile glass rod and inserted into a 
clean glass tube containing 3% (V/V) hydrogen peroxide solution. Production of 
gas bubbles is interpreted as positive test and no gas bubbles as negative test. 
 
3. Coagulase test 
 Slide coagulase test: a clean glass slide is divided into 2 portions with a glass 
marking pencil. A drop of normal saline is added to each portion. A colony of the 
test organism is picked up with a bacteriological loop and emulsified in each of the 
two drops. A drop of undiluted plasma is added to one of the 
suspensions.Clumping indicates the strain is coagulase positive. 
 Tube coagulase test: To 1 ml of 1:6 diluted plasma o.1 ml of broth culture of test 
organism is added and incubated at 37°C for 2- 4hrs. positive test is indicated 
when the coagulum formed does not flow out of the tube when it is tilted. 
4. Indole test 
Peptone                                            20gm 
Sodium chloride                                5 gm 
Distilled water                             1000 ml 
pH                                                  7.4 
Dispensed in tubes and sterilized by autoclaving at 121°C for 15 minutes. 
Kovac’s reagent 
Amyl/ Isoamyl alcohol                    150 ml 
p-Dimethyl-aminobenzaldehyde      10 gm 
Concentrated, Hydrochloric acid      50 ml 
Aldehyde was dissolved in alcohol and slowly acid was added. 
Method: The medium was inoculated and incubated at 37°C for 24 hours.0.5 ml of 
Kovac’s reagent was added gently. Positive: Red coloured ring. Negative: Yellow colour 
5. Triple sugar Iron Medium 
Beef extract                              3 gm 
Yeast extract                             3 gm 
Peptone                                    20gm 
Glucose                                     1 gm 
Sucrose                                       10 gm 
Lactose                                       10 gm 
Ferric citrate                              0.3 gm 
Sodium chloride                           5 gm 
Sodium thiosulphate                  0.3 gm 
   Agar                                            12 gm 
Phenol red, 0.2% solution           12 ml 
Distilled water                         1000 ml 
The solids were dissolved by heating; indicator solution was added and and poured 
in tubes. Sterilized by autoclaving at 121°C for 15 minutes and cooled to form 
slopes to form deep (3 cm) butts. 
6. Nitrate reduction test 
Potassium nitrate                  0.2 gm 
Peptone                                    5 gm 
Distilled water                   1000 ml 
Dispensed in 5 ml tubes and autoclaved at 121°C for 15 minutes. 
Test reagent: Solution A: Sulfanilic acid 
                     Solution B: α-naphthylamine 
Solution A and B were mixed in equal amounts just before use to prepare the test reagent. 
The medium was inoculated and incubated for 96 hours. 0.1 ml of test reagent was added 
to the culture. A red colour developing within minutes indicated the presence of nitrite 
and hence the ability of organism to reduce nitrates. 
7. Hugh- Leifson’s Oxidation /Fermentation test 
Peptone                                                      20gm 
Sodium chloride                                         5 gm 
Dipotassium hydrogen phosphate              0.3 gm 
Bromothymol blue (1% aqueous solution)  3 ml 
Agar                                                             3gm  
Distilled water                                            1000 ml 
Duplicate tubes of medium are inoculated by stabbing; one tube is promptly covered with 
a layer of sterile melted petroleum jelly to a depth of 5-10 mm and both are incubated at 
37°C for up to 30 days.  
8. Christensen’s urease medium 
Peptone                                                      1gm 
Sodium chloride                                         5 gm 
Dipotassium hydrogen phosphate              2 gm 
Phenol red                                                   6 ml 
Agar                                                             20gm  
Distilled water                                            1000 ml 
10% sterile glucose solution                      10ml 
20% urea solution                                      100 ml 
Sterilize the glucose and urea solutions by filtration. Prepare basal medium without 
glucose and urea and adjust pH to 6.8-6.9 and sterilize by autoclaving in a flask at 121°C 
for 30 min. Cool to 50°C, add glucose and urea and tube the medium as slopes. 
9. Simmon’s citrate medium 
Koser’s medium                      1000ml 
Agar                                          20 gm 
Bromothymol blue 0.2%           40 ml 
Dispense, autoclave at 121°C for 15 min at 15 psi and allow to set as slopes. 
10. Glucose phosphate broth 
Peptone                                                      5gm 
Dipotassium hydrogen phosphate              5 gm 
Distilled water                                          1000 ml 
10% Glucose solution                                 50 ml 
Dissolve the peptone and phosphate and adjust the pH to 7.6. Filter, dispense in 5 ml 
amounts and sterilize by autoclaving at 121°C for 15 min at 15 psi. Sterilize glucose 
solution by filtration and add 0.25 ml to each tube. 
Methyl red reagent 
Methyl red                10gm 
Ethyl alcohol             30 ml 
Distilled water          20ml 
Voges Proskauer reagent 
Reagent A: Alpha naphthol    5gm 
                     Ethyl alcohol    100 ml 
Reagent B: Potassium hydroxide      40 gm 
                     Distilled water            100 ml 
11. Phenylalanine deaminase test 
Yeast extract                                 3gm 
DL phenylalanine                         2 gm 
Di sodium hydrogen phosphate    1 gm 
Sodium chloride                            5gm 
Agar                                              12 gm 
Distilled water                                1000ml 
pH                                                7.4 
Distributed in tubes and sterilized by autoclaving at 121°C for 15 min at 15 psi, 
allowed to solidify as long slopes. 
12. Aminoacid decarboxylase and arginine dihydrolase test 
Peptone                                                       5gm 
Meat extract                                                5 gm 
Glucose                                                      0.5 gm 
Pyridoxal                                                   5 mg 
Bromocresol purple (1in 500 solution)      5 ml 
Cresol red (1in 500 solution)                   2.5 ml 
Distilled water                                1000ml 
Dissolve the solids in water and adjust the pH to 6 before the addition of 
indicators. Divide the basal medium into four portions and treat separately as 
follows: add 1% L-lysine hydrochloride, add 1% L-ornithine hydrochloride, add 
1% L-arginine hydrochloride, No additions. Distribute in 1ml amounts in small 
test tubes containing sterile liquid paraffin to provide a layer about 5mm above the 
medium. Sterilize by autoclaving at 121°C for 15 min at 15 psi. 
13. Bile esculin Hydrolysis test 
Meat extract             3 gm 
Peptone                    5 gm 
Ox bile purified and dehydrated         10 gm 
Aesculin  1gm 
Ferric ammonium citrate   0.5 gm 
Sodium chloride                            5gm 
Agar                                              15 gm 
Distilled water                                1000ml 
While heating, dissolve the meat extract, peptone, Nacl and agar in 400 ml water, 
the ox bile in 400ml, the ferric ammonium citrate in 100ml. Mix the solutions, 
adjust to pH 7.0, autoclave at 121°C for 15 min and cool to 50 °C. Dissolve the 
aesculin in 100 ml water, sterilize by filtration, and add to the basal medium at  
50 °C , dispense as slopes and store at 4 °C. 
14. Carbohydrate Fermentation media 
To the basal medium of peptone water, add sterilized sugars of 1% and indicator 
bromothymol blue.  
Sugars to be tested generally are: Glucose, Sucrose, Lactose, Maltose, Mannitol. 
Distribute 3ml amounts in standard test tubes with inverted Durham’s tube. 
Sterilize by steaming at 100°C for 30 min on 3 consecutive days. 
 
 
 
 
         
 
 

ANNEXURE II 
PROFORMA 
 Name :                                                              OP NO: 
 Age:                                                                   Ward: 
 Sex: 
 Occupation: 
 Address: 
 
Presenting complaints: 
 
Past history:  
 
Personal history: 
• Alcohol intake: 
• Cigarette smoking: 
Associated immunocompromised state: 
• Pregnancy 
• Known tuberculosis patient / HIV 
• Bleeding disorders 
• Diabetes mellitus 
• Genitourinary Malignancy/on Chemotherapy 
• Transplant recipient  
 Radiological Investigations: X-ray KUB / USG Abdomen / CT scan  
 
Provisional diagnosis / Indication for ureteral stenting: 
 
Laboratory evaluation: 
Biochemical parameters: 
 Plasma glucose levels 
  Blood urea 
 Creatinine  
Hematological investigations: 
 TC 
 DC 
 Hb estimation 
 ESR 
Microbiological investigation: 
Sample collected: 
 Mid stream Clean Catch Urine 
 Double-J Ureteral Stent tip 
Direct examination: 
 Gram stain: 
 KOH mount: 
Bacterial Culture: 
 MacConkey Agar plate 
 5% sheep Blood Agar plate 
Fungal culture: 
 2 Sabouraud dextrose agar slopes with antibiotics 
Maki’s roll plate Semiquantitative Culture of Double-J Ureteral Stent proximal tip: 
Isolate identified in Urine sample: 
Isolate identified in Double-J Ureteral Stent tip: 
Antimicrobial susceptibility pattern: 
ANNEXURE III 
PATIENT CONSENT FORM 
TITLE OF THE STUDY : “Study on Lower Urinary tract Infections and 
stent colonization in patients with Double- J Ureteral stents in a tertiary care 
hospital’’ 
 
Name :        Date  : 
Age :        OP No :  
Sex :        Project Patient No : 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has 
been read to me). I was free to ask any questions and they have been answered. I hereby 
give my consent to be included as a participant in “Study on Lower Urinary tract 
Infections and stent colonization in patients with Double- J Ureteral stents in a 
tertiary care hospital’’ 
I have read and understood this consent form and the information provided to me. 
1. I have had the consent document explained to me. 
2. I have been explained about the nature of the study. 
3. I have been explained about my rights and responsibilities by the investigator.  
4. I have informed the investigator of all the treatments I am taking or have taken in the 
past ________ months including any native (alternative) treatment. 
5. I have been advised about the risks associated with my participation in this study. 
6. I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms. 
7. I have not participated in any research study within the past ________ month(s). 
8. I am aware of the fact that I can opt out of the study at any time without having to 
give my reason and this will not affect my future treatment in this hospital. 
9. I am also aware that the investigator may terminate my participation in the study at 
any time, for any reason, without any consent. 
10. I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
11. I have understood that my identity will be kept confidential if my data are publicly 
presented. 
12. I have had my questions answered to my satisfaction. 
13. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the investigator. 
By signing this consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. 
For participants: 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent/ For age 10-17 yrs-Name& signature of the parent/guardian.) 
Name ___________________________________ 
Signature_________________________  
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ___________________________________ 
Signature_________________________  
Date________________ 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
Name ___________________________________ 
Signature_________________________  
Date_______________ 
S. 
NO
I.P NO AGE SEX DIAGNOSIS
COMOR
BIDTIES
INDICATION FOR DOUBLE J 
STENT PLACEMENT
SIDE OF 
DOUBLE -J 
STENT 
PLACEME
NT
INDWELL
ING TIME 
OF 
DOUBLE-
JURETER
AL STENT
URINE CULTURE
DOUBLE-J STENT 
PROXIMAL TIP CULTURE
AMPI 
(10μg)
AK
(30μg)
1 11041/47 40 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 6 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
2 11030/47 45 F R renal calculus DM ESWL Right 5 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
3 9674/47 55 F R PUJ calculus Nil URS stone Extraction/Lithotripsy Right 3.57 No growth No growth ˗ ˗
4 12830/47 57 F L Renal calculus DM/HTN Hydronephrosis Left 3 No growth Klebsiella oxytoca N S
5 12760/47 31 M L  ureteric calculus Nil ESWL Left 3.43 No growth Pseudomonas aeruginosa N S
6 10956/47 25 M L Renal calculus Nil URS stone Extraction/Lithotripsy Left 9 Pseudomonas aeruginosa Pseudomonas aeruginosa N S
5 Pseudomonas aeruginosa, Pseudomonas aeruginosa N S
3.71 Staphylococcus epidermidis N N
8 13020/47 49 F L  midureteric calculus + HUN Nil URS stone Extraction/Lithotripsy Left 3 Enterococcus faecalis Enterococcus faecalis R N
9 173/47 55 M R renal calculus+RPUJ Calculus Nil After PCNL Right 3 Escherichia coli Escherichia coli R R
10 1531/47 26 M R Renal calculus Nil After PCNL Right 6 Escherichia coli Escherichia coli R S
11 12842/47 20 F R Renal calculus Nil URS stone Extraction/Lithotripsy Right 4 Klebsiella oxytoca Klebsiella oxytoca N R
12 108062/47 40 F R Renal calculus Nil ESWL Right 3 No growth No growth ˗ ˗
13 11638/47 52 M R Renal calculus Nil ESWL Right 3 No growth No growth ˗ ˗
14 610/47 42 F L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 7 No growth Escherichia coli R R
15 12375/47 45 F Rmid ureteric stricture + HUN Nil Ureteropyelostomy Right 6 Escherichia coli Escherichia coli R S
16 2590/47 50 M R renal calculus Nil After PCNL Right 6 Escherichia coli Escherichia coli R R
17 12978/47 44 M L upper ureteric calculus Nil Open ureterolithotomy Left 3 Escherichia coli Escherichia coli R R
18 13059/45 24 M R lower ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth Escherichia coli R R
19 1379/47 38 F L VUJ calculus Nil URS stone Extraction/Lithotripsy Left 3 Escherichia coli Escherichia coli R R
20 11053/47 24 F R renal calculus Nil URS stone Extraction/Lithotripsy Right 2.5 No growth Klebsiella oxytoca N R
21 143/47 43 M R lower ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth Pseudomonas aeruginosa N R
22 1176/47 30 F L renal calculus Nil ESWL Left 2.5 No growth Klebsiella oxytoca N R
23 436/47 50 M R Pelvic calculus Nil ESWL Right 4.14 No growth No growth ˗ ˗
24 3762/47 32 F R upper ureteric calculus Nil URS stone Extraction/Lithotripsy Right 5 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
25 944/47 30 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
26 11118/47 35 M L Pelvic calculus Nil After PCNL Left 3.5 No growth No growth ˗ ˗
27 6596/47 60 M L renal calculus DM After PCNL Left 5 Candida tropicalis Candida tropicalis N N
28 1726/47 63 M L Renal calculus Nil After PCNL Left 7 No growth Klebsiella oxytoca N S
29 9087/47 29 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
30 592/47 50 M L lower ureteric calculus Nil URS stone Extraction/Lithotripsy Left 4.71 No growth Escherichia coli R S
31 802/47 53 M L  ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3 No growth Escherichia coli R S
32 16547/47 30 M L lower ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2 No growth No growth ˗ ˗
33 1356/47 60 F R renal calculus +R VUJ calculus Nil After PCNL Right 15 No growth No growth ˗ ˗
34 10886/47 60 F R staghorn calculus HTN After PCNL Right 5 Staphylococcus aureus Staphylococcus aureus N N
35 7135/47 50 F R renal calculus Nil After PCNL Right 3 Escherichia coli Escherichia coli S R
36 13749/47 28 M R VUJ calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth Escherichia coli R R
37 726/47 37 F Rlower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth No growth ˗ ˗
38 15366/47 33 F R lower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2.5 Candida tropicalis Candida tropicalis N N
39 14328/47 21 F R VUJ calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth No growth ˗ ˗
7 11345/47 52 F L upper ureteric calculus DM URS stone Extraction/Lithotripsy Left
40 14391/47 29 F L renal calculus Nil After PCNL Left 2.7 Candida tropicalis Candida tropicalis N N
41 14029/47 34 F R lower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2.5 No growth No growth ˗ ˗
42 12385/47 30 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.43 Pseudomonas aeruginosa Pseudomonas aeruginosa ˗ S
43 18292/47 39 M L lower ureteric calculus DM URS stone Extraction/Lithotripsy Left 3.86 No growth No growth ˗ ˗
44 941/47 25 M L VUJ calculus Nil URS stone Extraction/Lithotripsy Left 5.86 Pseudomonas aeruginosa Pseudomonas aeruginosa N R
45 10987/47 75 M BPH+ L HUN Nil Hydronephrosis Left 13.6 Klebsiella oxytoca Klebsiella oxytoca N R
46 12234/47 50 M L VUJ calculus Nil ESWL Left 13.86 Klebsiella oxytoca Klebsiella oxytoca N R
47 6608/47 60 M L renal calculus Nil After PCNL Left 3.14 Escherichia coli Escherichia coli R R
48 1301/47 38 M R lower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3.5 No growth Staphylococcus aureus N N
49 19763/47 47 M L VUJ calculus+vesical calculus Nil Vesiculolithaloplasty Left 2 No growth Escherichia coli R R
50 4498/47 39 F L lower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.42 No growth No growth ˗ ˗
51 20899/47 65 M L upper ureteric calculus DM URS stone Extraction/Lithotripsy Left 5.3 No growth No growth ˗ ˗
52 84151/47 38 M R upper  Ureteric calculus Nil Ureterocalicostomy Right 3.43 Klebsiella oxytoca Klebsiella oxytoca N S
53 21174/47 38 M R upper Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3 No growth No growth ˗ ˗
54 10292/47 27 F R lower ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2 No growth No growth ˗ ˗
55 10345/47 32 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.57 No growth No growth ˗ ˗
56 1278/47 42 M R Renal calculus Nil After PCNL Right 3.43 No growth Escherichia coli R S
57 1737/47 45 M R lower  Ureteric calculus DM/HTN URS stone Extraction/Lithotripsy Right 2.43 Klebsiella oxytoca Klebsiella oxytoca N S
58 30035/47 26 M L PUJ calculus Nil URS stone Extraction/Lithotripsy Left 2.43 No growth Staphylococcus aureus N N
59 2129/47 48 F L VUJ calculus Nil URS stone Extraction/Lithotripsy Left 2.14 No growth Staphylococcus aureus N N
60 2187/47 42 F R VUJ calculus Nil URS stone Extraction/Lithotripsy Right 3.29 No growth No growth ˗ ˗
61 26663/47 24 M R upper Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 3.29 No growth No growth ˗ ˗
62 31073/47 40 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3.29 No growth No growth ˗ ˗
63 27095/47 41 M L lower ureteric calculus DM URS stone Extraction/Lithotripsy Left 4.29 No growth No growth ˗ ˗
64 25641/47 65 F R lower  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2.86 No growth No growth ˗ ˗
65 26865/47 29 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3.43 No growth No growth ˗ ˗
66 31620/47 28 M R Renal calculus Nil Pyelolithotomy Right 5.14 No growth No growth ˗ ˗
67 37649/47 38 F L upper ureteric calculus DM URS stone Extraction/Lithotripsy Left 11.43 Escherichia coli Escherichia coli R S
68 16161/47 50 F R Pelvic calculus HTN After PCNL Right 3.43 Enterococcus faecalis Enterococcus faecalis R N
69 39522/47 21 M R upper Ureteric calculus Nil ESWL Right 8.43 Escherichia coli Escherichia coli R S
70 19781/47 52 M L renal calculus Nil After PCNL Left 2.29 Escherichia coli Escherichia coli R S
71 132052/47 30 M R upper Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 6.29 No growth No growth ˗ ˗
72 32414/47 60 F R upper Ureteric calculus DM/HTN URS stone Extraction/Lithotripsy Right 2.43 Escherichia coli Escherichia coli R S
73 42037/47 36 M R VUJ calculus Nil URS stone Extraction/Lithotripsy Right 2.43 No growth No growth ˗ ˗
74 37962/47 65 F R mid Ureteric calculus + HUN Nil URS stone Extraction/Lithotripsy Right 3.86 No growth Pseudomonas aeruginosa N S
75 36359/47 41 M R Pelvic calculus DM/HTN After PCNL Right 3.29 No growth Staphylococcus epidermidis N N
76 42913/47 49 M L renal calculus Nil URS stone Extraction/Lithotripsy Left 3.71 No growth No growth ˗ ˗
77 39602/47 38 M R upper ureteric calculus DM URS stone Extraction/Lithotripsy Right 3 Klebsiella pneumoniae Klebsiella pneumoniae N S
78 27610/47 20 F L renal calculus Nil After PCNL Left 2.29 No growth Candida krusei N N
79 44447/47 32 F L renal calculus Nil ESWL Left 2.57 No growth Pseudomonas aeruginosa N S
80 43830/47 32 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.29 No growth Pseudomonas aeruginosa N S
81 43892/47 27 F R upper ureteric calculus Nil URS stone Extraction/Lithotripsy Right 6.29 No growth Enterococcus faecalis R N
82 33768/47 40 F R upper  Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2.29 Escherichia coli Escherichia coli R S
83 44311/47 27 F L lower ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.43 No growth Enterococcus faecalis R N
84 45210/47 27 F R mid Ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2 No growth Pseudomonas aeruginosa N S
85 48087/47 21 F R lower ureteric calculus Nil URS stone Extraction/Lithotripsy Right 2 No growth Klebsiella oxytoca N R
86 49051/47 48 F L VUJ calculus Nil URS stone Extraction/Lithotripsy Left 4.57 No growth Escherichia coli R S
87 47851/47 50 F L Pelvic calculus Nil ESWL Left 2.57 Pseudomonas aeruginosa Pseudomonas aeruginosa N S
88 47852/47 45 F L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3.14 No growth No growth ˗ ˗
89 48344/47 51 F L Pelvic calculus Nil ESWL Left 2.57 No growth No growth ˗ ˗
90 43578/47 45 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3 No growth Pseudomonas aeruginosa N S
91 47813/47 32 F L lower ureteric calculus Nil URS stone Extraction/Lithotripsy Left 3.43 No growth Klebsiella oxytoca N R
92 46536/47 32 M L renal calculus Nil After PCNL Left 3 No growth Escherichia coli R R
93 58024/47 30 F R renal calculus Nil ESWL Right 3 No growth Acinetobacter baumanii N S
94 55365/47 35 F R VUJ calculus Nil URS stone Extraction/Lithotripsy Right No growth No growth ˗ ˗
Klebsiella pneumoniae N S
Staphylococcus epidermidis N N
Pseudomonas aeruginosa N R
3.43 Enterococcus faecalis R N
97 58038/47 62 F R lower ureteric calculus + HUN Nil URS stone Extraction/Lithotripsy Right 3.14 No growth No growth ˗ ˗
98 58082/47 44 F L renal calculus Nil ESWL Left 2.57 No growth No growth ˗ ˗
99 57931/47 38 M L lower ureteric calculus Nil URS stone Extraction/Lithotripsy Left 2.43 No growth No growth ˗ ˗
100 58076/47 35 F R upper ureteric calculus Nil URS stone Extraction/Lithotripsy Right No growth No growth ˗ ˗
Pseudomonas aeruginosa
No growth
96 53860/47 26 M L upper ureteric calculus Nil URS stone Extraction/Lithotripsy Left
95 58028/47 62 F R renal calculus
3.86
5.86
Nil ESWL Right
GM
(10µg)
CIP
(5μg)
OF
(5μg)
NX
(10μg)
TMP/SMX
(1.25/
23.75μg)
NITRO
(300μg)
CTX
(30μg)
CAZ
(30μg)
TE
(30μg)
IPM
(10μg)
PT
(100/10μg)
P(10U)
HLG
(120μg)
LZ 
(30µg)
VANCO
(30μg)
FLU
(25µg)
VRC
(1µg)
MIC MRP 
μg/ml
MIC 
VANCO 
μg/ml
MIC 
AMB 
µg/ml
ESBL MBL AmpC MR
BIOFILM 
FORMATION
R R S S N N N S N S S N N N N N N N N N N N N N Weak 
S R R S N N N S N S S N N N N N N N N N N N N N Non biofilm
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ N ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S R R R R R R R R S S N N N N N N N N N N N N N Moderate
S R R R N N N R N S R N N N N N N N N N N N N N Non biofilm
R R R S N N N R N S R N N N N N N N N N N N N N Weak
S S R R N N N R N S R N N N N N N N N N N N N N Strong 
N S S N S S S N S N N R N S N N N N N N N N N N N
N S N R N R N N S N N R S S S N N N N N N N N N Moderate
R R R R R S R R S S R N N N N N N N N N + N N N Strong
R R R S R S R R S R R N N N N N N 16   R N N + + N N Strong
R R R S R R R R R S R N N N N N N N N N + N N N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R R R R R R R S S S N N N N N N N N N + N N N Strong
S R R R R S R R R S R N N N N N N N N N + N N N Moderate
R R R R R R R R R R R N N N N N N 32 N N + + N N Strong
R R R R R R R R R R R N N N N N N 32 N N + + N N Strong
S R R S R R S S S S S N N N N N N N N N N N + N Weak
R R R S R S R R R S R N N N N N N N N N + N N N Strong 
R R R R R S R R R R R N N N N N N 32 N N + + N N Strong
R R R R N N N R N S S N N N N N N N N N N N N N Moderate
R R R S S R R S S R S N N N N N N 16 N N N + N N Strong
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R S S N N N R N S R N N N N N N N N N N N + N Strong
R S R R N N N R N S R N N N N N N N N N N N + N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
N N N N N N N N N N N N N N N S S N N 1 N N N N Strong
S S S S S S S S S S S N N N N N N N N N N N N N Nonbiofilm
R R S R N N N R N S S N N N N N N N N N N N N N Moderate
R R S R S S R S S S S N N N N N N N N N N N N N Nonbiofilm
R R R S S S S S R S S N N N N N N N N N N N N N Nonbiofilm
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R N R R S N N S N N R N N N N N N 1 N N N N + Strong
R S R R R S R R S S S N N N N N N N N N + N N N weak
R R S R R S R R R S S N N N N N N N N N + N N N weak
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
N N N N N N N N N N N N N N N R R N N 0.5 N N N N Strong
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
N N N N N N N N N N N N N N N R R N N 0.5 N N N N Strong
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S S S S N N N S N S S N N N N N N N N N N N N N Nonbiofilm
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S S R R N N N R N R R N N N N N N 16 N N N + N N Strong
R R R R R S R R R S R N N N N N N N N N + N N N Weak
R R R R R R R R S S R N N N N N N N N N + N N N Moderate
R R S R R S S S R S S N N N N N N N N N N N N N Nonbiofilm
S R N R R S N N S N N R N S N N N N 2 N N N N + Strong
R R R R S S R R R S R ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ + ˗ ˗ ˗ Strong
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S S S S S S S S S S S N N N N N N N N N N N N N Nonbiofilm
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S S R R R R R R R S R N N N N N N N N N N + N N moderate
R R R S S S R R R S S N N N N N N N N N + N N N Moderate
R R N S R S N N S N N R N S N N N N N N N N N N Moderate
S R N S R S N N S N N R N S N N N N N N N N N N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S S R R S S R S R S S N N N N N N N N N + N N N Weak
N R N R N R N N S N N R S S S N N N N N N N N N weak
R R S S R S R R R S R N N N N N N N N N + N N N Strong
R R R R S R R S R S S N N N N N N N N N + N N N Nonbiofilm
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R S S R R R R S S S N N N N N N N N N + N N N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R R R N N N R N S S N N N N N N N N N N N N N Strong
S S N S S S N N S N N R N S N N N N N N N N N N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R R R R R R R R S S S N N N N N N N N N + N N N weak
N N N N N N N N N N N N N N N R R N N 1 N N N N Strong
S R R R N N N R N S R N N N N N N N N N N N N N Strong
S R R R N N N R N R R N N N N N N 32 N N N + N N Moderate
N R N N N S N N R N N R S S S N N N N N N N N N Strong
S S S S R S R R R S S N N N N N N N N N N N N N Strong
N R N R N S N N S N N R S S S N N N N N N N N N Strong
S R R R N N N S N S S N N N N N N N N N N N N N Weak
R R R R R R R R S S S N N N N N N N N N N N + N Strong
S R S S R R R R S R S S N N N N N N N N + N N ˗ Moderate
S S R S N N N S N S S N N N N N N N N N N N + ˗ weak
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
S R R S N N N S N S S N N N N N N N N N N N N N weak
R R R R S S R R S S R N N N N N N N N N N N + N Strong
R R R S S S R R R S R N N N N N N N N N + N N N Moderate
S S ˗ ˗ S ˗ S S S S S N N N N N N N N N N N N N Moderate
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
R S S S S R R R S S S N N N N N N N N N + N N N Moderate
R R N R R R N N R N N R N S N N N N 4 N N N N + Moderate 
R R R R N N N R N S S N N N N N N N N N N N N N Strong
N R N R N S N N S N N R S S S N N N N N N N N N ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗ ˗
KEY TO MASTER CHART 
 
M : Male 
F :  Female 
S :  Sensitive 
R : Resistant 
N : Not tested 
Ampi : Ampicillin 
AK : Amikacin 
GM : Gentamicin 
Cip : Ciprofloxacin 
OF : Ofloxacin 
NX : Norfloxacin 
TMP/SMX : Trimethoprim/ Sulfamethoxazole 
Nitro : Nitrofurantoin 
CTX : Cefotaxime 
CAZ : Ceftazidime 
TE : Tetracycline 
IPM : Imipenem 
PT : Piperacillin-Tazobactum 
P : Pencillin 
HLG : High-level Gentamicin 
LZ : Linezolid 
Vanco : Vancomycin 
FLU : Fluconazole 
VRC : Voriconazole 
MRP : Meropenem 
AMB : Amphotericin B 
ESBL : Extended spectrum beta lactamases 
MBL : Metallo beta lactamases 
MR : Methicillin Resistance 
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